Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Leukemia

  Free Subscription


Articles published in Leuk Lymphoma

Retrieve available abstracts of 421 articles:
HTML format
Text format



Single Articles


    October 2019
  1. KOHART NA, Elshafae SM, Demirer AA, Dirksen WP, et al
    Parathyroid hormone-related protein promotes bone loss in T-cell leukemia as well as in solid tumors.
    Leuk Lymphoma. 2019 Oct 8:1-11. doi: 10.1080/10428194.2019.1672055.
    PubMed     Text format     Abstract available


  2. LECAT CSY, Besley C, Hough RE, Khwaja A, et al
    Inotuzumab ozogamicin versus FLAG-Ida in the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia - real-world resource use data.
    Leuk Lymphoma. 2019 Oct 3:1-3. doi: 10.1080/10428194.2019.1672057.
    PubMed     Text format    


    September 2019
  3. ALFAYEZ M, Thakral B, Jain P, Ravandi F, et al
    First report of clinical response to venetoclax combination with pentostatin in T-cell-prolymphocytic leukemia (T-PLL).
    Leuk Lymphoma. 2019 Sep 30:1-5. doi: 10.1080/10428194.2019.1660967.
    PubMed     Text format    


  4. MYLES N, Giri P, Chim I, Kodituwakku A, et al
    The utility of CD200 expression and modified Matutes score in the diagnostic differentiation of mantle cell lymphoma and chronic lymphocytic leukemia using flow cytometry.
    Leuk Lymphoma. 2019 Sep 27:1-3. doi: 10.1080/10428194.2019.1663420.
    PubMed     Text format    


  5. FAZIO F, Barberi W, Cazzaniga G, Fazio G, et al
    Efficacy of imatinib and chemotherapy in a pediatric patient with Philadelphia-like acute lymphoblastic leukemia with Ebf1-Pdgfrb fusion transcript.
    Leuk Lymphoma. 2019 Sep 27:1-4. doi: 10.1080/10428194.2019.1668938.
    PubMed     Text format    


  6. GURBUXANI S
    Lymphoblastic leukemia following MDS or MDS/MPN: clinical evidence for stem cell origins of these disorders.
    Leuk Lymphoma. 2019 Sep 26:1-2. doi: 10.1080/10428194.2019.1666382.
    PubMed     Text format    


  7. ANDREWS C, Lipton J
    The role of ponatinib in chronic myeloid leukemia in the era of treatment free remission.
    Leuk Lymphoma. 2019 Sep 26:1-3. doi: 10.1080/10428194.2019.1665667.
    PubMed     Text format    


  8. DENG R, Gibiansky L, Lu T, Li X, et al
    Exposure-response analysis of venetoclax in combination with rituximab in patients with relapsed or refractory chronic lymphocytic leukemia: pooled results from a phase 1b study and the phase 3 MURANO study.
    Leuk Lymphoma. 2019 Sep 24:1-10. doi: 10.1080/10428194.2019.1657575.
    PubMed     Text format     Abstract available


  9. MULLIGAN SP, Shumack S, Guminski A
    Chronic lymphocytic leukemia, skin and other second cancers.
    Leuk Lymphoma. 2019 Sep 24:1-3. doi: 10.1080/10428194.2019.1665669.
    PubMed     Text format    


  10. ZHANG H, Ying H, Wang X
    Methyltransferase DNMT3B in leukemia.
    Leuk Lymphoma. 2019 Sep 24:1-11. doi: 10.1080/10428194.2019.1666377.
    PubMed     Text format     Abstract available


  11. BHATNAGAR B, Zhao Q, Mims AS, Vasu S, et al
    Selinexor in combination with decitabine in patients with acute myeloid leukemia: results from a phase 1 study.
    Leuk Lymphoma. 2019 Sep 23:1-10. doi: 10.1080/10428194.2019.1665664.
    PubMed     Text format     Abstract available


  12. XU H, Liu J, Shen N, Zhao Z, et al
    The interaction of tumor cells and myeloid-derived suppressor cells in chronic myelogenous leukemia.
    Leuk Lymphoma. 2019 Sep 18:1-10. doi: 10.1080/10428194.2019.1658098.
    PubMed     Text format     Abstract available


  13. SEA JL, Orgel E, Chen T, Paszkiewicz RL, et al
    Levocarnitine does not impair chemotherapy cytotoxicity against acute lymphoblastic leukemia.
    Leuk Lymphoma. 2019 Sep 16:1-9. doi: 10.1080/10428194.2019.1666379.
    PubMed     Text format     Abstract available


  14. OKABE S, Tanaka Y, Moriyama M, Gotoh A, et al
    Efficacy of dasatinib against ponatinib-resistant chronic myeloid leukemia cells.
    Leuk Lymphoma. 2019 Sep 10:1-3. doi: 10.1080/10428194.2019.1660971.
    PubMed     Text format    


  15. YANG Q, Qian H, Jin Z, Yu Z, et al
    SET-CAN fusion gene as poor prognosis predictor in adult T-cell acute lymphoblastic leukemia.
    Leuk Lymphoma. 2019 Sep 10:1-4. doi: 10.1080/10428194.2019.1660966.
    PubMed     Text format    


  16. NAGAI Y, Tsukamoto S, Hino Y, Isshiki Y, et al
    Remarkable donor-derived T cell lymphocytosis before engraftment of a bone marrow transplant for acute lymphoblastic leukemia.
    Leuk Lymphoma. 2019 Sep 5:1-4. doi: 10.1080/10428194.2019.1660973.
    PubMed     Text format    


  17. LANVERS-KAMINSKY C, Niemann A, Eveslage M, Beck J, et al
    Asparaginase activities during intensified treatment with pegylated E. coli asparaginase in adults with newly-diagnosed acute lymphoblastic leukemia.
    Leuk Lymphoma. 2019 Sep 3:1-8. doi: 10.1080/10428194.2019.1658099.
    PubMed     Text format     Abstract available


    August 2019
  18. ADVANI AS, Hanna R
    The treatment of adolescents and young adults with acute lymphoblastic leukemia.
    Leuk Lymphoma. 2019 Aug 27:1-9. doi: 10.1080/10428194.2019.1658103.
    PubMed     Text format     Abstract available


  19. CORTES J, Huynh L, Mendelson E, Brandt P, et al
    Treatment patterns and deep molecular response in chronic phase - chronic myeloid leukemia patients treated with second-line nilotinib or dasatinib: a multi-country retrospective chart review study.
    Leuk Lymphoma. 2019 Aug 13:1-10. doi: 10.1080/10428194.2019.1644332.
    PubMed     Text format     Abstract available


  20. WONG E, Davis J, Koldej R, Szer J, et al
    Nivolumab induces dynamic alterations in CD8 T-cell function and TIM-3 expression when used to treat relapsed acute myeloid leukemia after allogeneic stem cell transplantation.
    Leuk Lymphoma. 2019 Aug 7:1-4. doi: 10.1080/10428194.2019.1648803.
    PubMed     Text format    


  21. RATAJCZAK B, Gniot M, Przybylowicz-Chalecka A, Czerwinska-Rybak J, et al
    Characterization and significance of the Philadelphia negative/BCR-ABL1 positive rearrangement or masked Philadelphia translocation in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a single-center study.
    Leuk Lymphoma. 2019 Aug 7:1-5. doi: 10.1080/10428194.2019.1648807.
    PubMed     Text format    


  22. PRIETO-CONDE MI, Labrador J, Hermida G, Alonso S, et al
    Genomic analysis of a familial myelodysplasia/acute myeloid leukemia and inherited RUNX1 mutations without a pre-existing platelet disorder.
    Leuk Lymphoma. 2019 Aug 6:1-4. doi: 10.1080/10428194.2019.1648801.
    PubMed     Text format    


    July 2019
  23. GU JX, Zhang N, Li SS, Zhang AM, et al
    The detection of bacterial infections in leukemia patients using procalcitionin levels.
    Leuk Lymphoma. 2019 Jul 27:1-6. doi: 10.1080/10428194.2019.1646906.
    PubMed     Text format     Abstract available


  24. ANDRITSOS LA, Byrd JC, Cheverton P, Wu J, et al
    A multicenter phase 1 study of plerixafor and rituximab in patients with chronic lymphocytic leukemia.
    Leuk Lymphoma. 2019 Jul 27:1-9. doi: 10.1080/10428194.2019.1643463.
    PubMed     Text format     Abstract available


  25. PAIGE E, Thursky K, Slavin M
    Mold-active prophylaxis in acute leukemia: not enough of a good thing?()
    Leuk Lymphoma. 2019 Jul 23:1-3. doi: 10.1080/10428194.2019.1641804.
    PubMed     Text format    


  26. KNORR DA, Goldberg AD, Stein EM, Tallman MS, et al
    Immunotherapy for acute myeloid leukemia: from allogeneic stem cell transplant to novel therapeutics.
    Leuk Lymphoma. 2019 Jul 23:1-13. doi: 10.1080/10428194.2019.1639167.
    PubMed     Text format     Abstract available


  27. DHAKAL P, Kaur J, Gundabolu K, Raj Bhatt V, et al
    Immunotherapeutic options for management of relapsed or refractory B-cell acute lymphoblastic leukemia: how to select newly approved agents?
    Leuk Lymphoma. 2019 Jul 18:1-11. doi: 10.1080/10428194.2019.1641802.
    PubMed     Text format     Abstract available


  28. CHEN Z, Mai W, Li Z, Zhang H, et al
    The epidemiological trend of acute promyelocytic leukemia over past four decades: a population-based analysis.
    Leuk Lymphoma. 2019 Jul 15:1-12. doi: 10.1080/10428194.2019.1639164.
    PubMed     Text format     Abstract available


  29. ALFAYEZ M, Burger JA, Kadia T, Xu TH, et al
    Plesiomonas shigelloides gastroenteritis in a patient with chronic lymphocytic leukemia.
    Leuk Lymphoma. 2019 Jul 15:1-2. doi: 10.1080/10428194.2019.1639171.
    PubMed     Text format    


  30. BARRETO JN, Cullen MW, Mara KC, Grove ME, et al
    QT prolongation in patients with acute leukemia or high-risk myelodysplastic syndrome prescribed antifungal prophylaxis during chemotherapy-induced neutropenia.
    Leuk Lymphoma. 2019 Jul 12:1-9. doi: 10.1080/10428194.2019.1639165.
    PubMed     Text format     Abstract available


  31. BASSAN R, Fumagalli M, Chiaretti S, Audisio E, et al
    Phase II trial with sequential clofarabine and cyclophosphamide for refractory and relapsed philadelphia-negative adult acute lymphoblastic leukemia. Results of the GIMEMA LAL 1610 protocol.
    Leuk Lymphoma. 2019 Jul 12:1-11. doi: 10.1080/10428194.2019.1639170.
    PubMed     Text format     Abstract available


  32. AUTORE F, Sora F, Chiusolo P, Annunziata M, et al
    'Secondary chronic myeloid leukemia': comparison between patients previously exposed or not to chemo- and/or radiotherapy.
    Leuk Lymphoma. 2019 Jul 11:1-3. doi: 10.1080/10428194.2019.1639162.
    PubMed     Text format    


  33. HICKEY E, Clemons B, Griffin S, Cox J, et al
    Multicenter evaluation of arsenic trioxide dosing in obese patients with low-intermediate risk acute promyelocytic leukemia.
    Leuk Lymphoma. 2019 Jul 11:1-4. doi: 10.1080/10428194.2019.1639163.
    PubMed     Text format    


  34. HARADA K, Tachibana T, Ohashi K, Ozawa Y, et al
    The effect of melphalan dose and total body irradiation as reduced-intensity conditioning for acute lymphoblastic leukemia patients undergoing allogeneic stem cell transplantation.
    Leuk Lymphoma. 2019 Jul 10:1-8. doi: 10.1080/10428194.2019.1636986.
    PubMed     Text format     Abstract available


  35. SHENG G, Xue M, Wang Q, Wen L, et al
    Occurrence of chromosomal abnormalities in Philadelphia chromosome-negative metaphases in patients with chronic-phase chronic myeloid leukemia undergoing TKI treatments.
    Leuk Lymphoma. 2019 Jul 8:1-9. doi: 10.1080/10428194.2019.1636984.
    PubMed     Text format     Abstract available


  36. MUESKE NM, Mittelman SD, Wren TAL, Gilsanz V, et al
    Myosteatosis in adolescents and young adults treated for acute lymphoblastic leukemia.
    Leuk Lymphoma. 2019 Jul 2:1-8. doi: 10.1080/10428194.2019.1623889.
    PubMed     Text format     Abstract available


  37. CHOE HK, van Besien K
    Donor graft genotypes versus leukemia.
    Leuk Lymphoma. 2019;60:1606-1607.
    PubMed     Text format    


  38. XUE M, Wang Q, Huo L, Wen L, et al
    Clinical characteristics and prognostic significance of chronic myeloid leukemia with rare BCR-ABL1 transcripts.
    Leuk Lymphoma. 2019 Jul 1:1-7. doi: 10.1080/10428194.2019.1607329.
    PubMed     Text format     Abstract available


  39. MEHER-HOMJI Z, Tam CS, Siderov J, Seymour JF, et al
    High prevalence of antibiotic allergies in cladribine-treated patients with hairy cell leukemia - lessons for immunopathogenesis and prescribing.
    Leuk Lymphoma. 2019 Jul 1:1-6. doi: 10.1080/10428194.2019.1633640.
    PubMed     Text format     Abstract available


  40. WANG F, Chen Y, Jiang N, Gong S, et al
    Acquired persistently complete remission by decitabine-based treatment for acute myeloid leukemia with the MLL-SEPT9 fusion gene.
    Leuk Lymphoma. 2019 Jul 1:1-4. doi: 10.1080/10428194.2019.1625044.
    PubMed     Text format    


    June 2019
  41. ISHDORJ G, Beiggi S, Nugent Z, Streu E, et al
    Risk factors for skin cancer and solid tumors in newly diagnosed patients with chronic lymphocytic leukemia and the impact of skin surveillance on survival.
    Leuk Lymphoma. 2019 Jun 25:1-10. doi: 10.1080/10428194.2019.1620941.
    PubMed     Text format     Abstract available


  42. TATE C, Burgess M, McMillan NA, Saunders NA, et al
    High serum levels of CD178 (soluble FasL) predict for inferior progression free survival in chronic lymphocytic leukemia treated with fludarabine-based chemotherapy.
    Leuk Lymphoma. 2019 Jun 25:1-5. doi: 10.1080/10428194.2019.1581936.
    PubMed     Text format    


  43. ROSSOFF J, Platanias LC
    Impact of myosteatosis in survivors of childhood acute lymphoblastic leukemia.
    Leuk Lymphoma. 2019 Jun 21:1-2. doi: 10.1080/10428194.2019.1630623.
    PubMed     Text format    


  44. SHAHRABI S, Maleknia M, Tavakolifar Y, D Zayeri Z, et al
    Neutropenia and leukemia development: genetic risk factors and prognosis.
    Leuk Lymphoma. 2019 Jun 19:1-12. doi: 10.1080/10428194.2019.1630622.
    PubMed     Text format     Abstract available


  45. STAHL M, Tallman MS
    Antibody-based therapy in acute leukemia - beware the risks.
    Leuk Lymphoma. 2019 Jun 17:1-2. doi: 10.1080/10428194.2019.1608535.
    PubMed     Text format    


  46. ACUNA-VILLAORDUNA A, Gonzalez-Lugo J, Ye BH, Adrianzen Herrera DA, et al
    High prevalence of pulmonary findings in computed tomographies of HTLV-1-infected patients with and without adult-T cell leukemia/lymphoma - implications for staging.
    Leuk Lymphoma. 2019 Jun 17:1-5. doi: 10.1080/10428194.2019.1627543.
    PubMed     Text format     Abstract available


  47. ASTORGUES-XERRI L, Vazquez R, Odore E, Rezai K, et al
    Insights into the cellular pharmacological properties of the BET-inhibitor OTX015/MK-8628 (birabresib), alone and in combination, in leukemia models.
    Leuk Lymphoma. 2019 Jun 17:1-4. doi: 10.1080/10428194.2019.1617860.
    PubMed     Text format    


  48. KIM B, Lee H, Kim E, Shin S, et al
    Clinical utility of targeted NGS panel with comprehensive bioinformatics analysis for patients with acute lymphoblastic leukemia.
    Leuk Lymphoma. 2019 Jun 17:1-8. doi: 10.1080/10428194.2019.1627538.
    PubMed     Text format     Abstract available


  49. XU D, Claudiani S, Naresh K, Mucklow S, et al
    Blast crisis of chronic myeloid leukemia with plasmacytoid dendritic cell phenotype associated with a rare fusion transcript, e13a3 BCR-ABL1.
    Leuk Lymphoma. 2019 Jun 11:1-2. doi: 10.1080/10428194.2019.1622101.
    PubMed     Text format    


  50. VASSEUR L, Lara D, Clappier E, Gillebert Q, et al
    Common clonal origin of an EBV-positive diffuse large B cell lymphoma and a chronic myelomonocytic leukemia.
    Leuk Lymphoma. 2019 Jun 11:1-3. doi: 10.1080/10428194.2019.1627539.
    PubMed     Text format    


  51. ELMAAGACLI AH, Salwender H, Jehn C, Dahmash F, et al
    Strong expression of SLAMF7 in natural killer/T-cell lymphoma and large granular lymphocyte leukemia - a prominent biomarker and potential target for anti-SLAMF7 antibody therapy.
    Leuk Lymphoma. 2019 Jun 4:1-4. doi: 10.1080/10428194.2019.1623887.
    PubMed     Text format    


  52. IBRAHIM M, Mendis N, Roma A, Jayanth P, et al
    Anti-leukemia effect of vitamin K3 is mediated through mitochondrial complexes I and II.
    Leuk Lymphoma. 2019 Jun 4:1-4. doi: 10.1080/10428194.2019.1620940.
    PubMed     Text format    


  53. CHEN LS, Keating MJ, Wierda WG, Gandhi V, et al
    Induction of apoptosis by MCL-1 inhibitors in chronic lymphocytic leukemia cells.
    Leuk Lymphoma. 2019 Jun 4:1-4. doi: 10.1080/10428194.2019.1622098.
    PubMed     Text format    


  54. DRAGANI M, Rege-Cambrin G, Ferrero D, Abruzzese E, et al
    Beyond the comfort zone of deep molecular response: discontinuation in major molecular response chronic myeloid leukemia.
    Leuk Lymphoma. 2019 Jun 4:1-3. doi: 10.1080/10428194.2019.1622103.
    PubMed     Text format    


  55. CERRANO M, Candoni A, Crisa E, Dubbini MV, et al
    FLAI induction regimen in elderly patients with acute myeloid leukemia.
    Leuk Lymphoma. 2019 Jun 4:1-2. doi: 10.1080/10428194.2019.1620943.
    PubMed     Text format    


  56. KIMURA K, Tsukamoto S, Takaishi K, Isshiki Y, et al
    T315I mutation with lymphoblasts in a newly diagnosed patient with chronic-phase chronic myeloid leukemia.
    Leuk Lymphoma. 2019;60:1591-1594.
    PubMed     Text format    


    May 2019
  57. ZAJAC-SPYCHALA O, Skalska-Sadowska J, Wachowiak J, Szmydki-Baran A, et al
    Infections in children with acute myeloid leukemia: increased mortality in relapsed/refractory patients.
    Leuk Lymphoma. 2019 May 28:1-8. doi: 10.1080/10428194.2019.1616185.
    PubMed     Text format     Abstract available


  58. BODDU P, Jain P, Borthakur G, Verstovsek S, et al
    Outcomes of patients with chronic phase chronic myeloid leukemia (CML-CP) after discontinuation of frontline ponatinib therapy.
    Leuk Lymphoma. 2019 May 24:1-9. doi: 10.1080/10428194.2019.1617862.
    PubMed     Text format     Abstract available


  59. KLOOS RQH, Pieters R, van den Bos C, van Eijkelenburg NKA, et al
    The effect of asparaginase therapy on methotrexate toxicity and efficacy in children with acute lymphoblastic leukemia.
    Leuk Lymphoma. 2019 May 23:1-9. doi: 10.1080/10428194.2019.1613537.
    PubMed     Text format     Abstract available


  60. CATTANEO C, Gramegna D, Malagola M, Pagani C, et al
    Invasive pulmonary aspergillosis in acute leukemia: a still frequent condition with a negative impact on the overall treatment outcome.
    Leuk Lymphoma. 2019 May 23:1-7. doi: 10.1080/10428194.2019.1613535.
    PubMed     Text format     Abstract available


  61. JOSEPH R, McRee AJ, Mathews S, Zeidner JF, et al
    Inversion 16 (inv(16)) acute myeloid leukemia (AML) following treatment with radiation, capecitabine, and temozolomide in a patient with metastatic neuroendocrine tumor (NET).
    Leuk Lymphoma. 2019 May 23:1-5. doi: 10.1080/10428194.2019.1612060.
    PubMed     Text format    


  62. BEST S, Liu T, Bruss N, Kittai A, et al
    Pharmacologic inhibition of the ubiquitin-activating enzyme induces ER stress and apoptosis in chronic lymphocytic leukemia and ibrutinib-resistant mantle cell lymphoma cells.
    Leuk Lymphoma. 2019 May 21:1-5. doi: 10.1080/10428194.2019.1616190.
    PubMed     Text format     Abstract available


  63. TORMO M, Gimenez E, Calabuig M, Talaya A, et al
    Cytomegalovirus DNAemia in patients with de novo acute myeloid leukemia undergoing cytotoxic chemotherapy.
    Leuk Lymphoma. 2019 May 21:1-3. doi: 10.1080/10428194.2019.1613541.
    PubMed     Text format    


  64. PUN CC, Lee KK, Chui YL
    C-terminal BRE inhibits cellular proliferation and increases sensitivity to chemotherapeutic drugs of MLL-AF9 acute myeloid leukemia cells.
    Leuk Lymphoma. 2019 May 21:1-9. doi: 10.1080/10428194.2019.1616184.
    PubMed     Text format     Abstract available


  65. DURAND M, Lacaria K, Sidsworth M, Davis MK, et al
    Management of cardiovascular health in acute leukemia: a national survey.
    Leuk Lymphoma. 2019 May 21:1-11. doi: 10.1080/10428194.2019.1613539.
    PubMed     Text format     Abstract available


  66. INNOCENTI I, Morelli F, Autore F, Tomasso A, et al
    Remission of acquired von Willebrand syndrome in a patient with chronic lymphocytic leukemia treated with venetoclax.
    Leuk Lymphoma. 2019 May 20:1-3. doi: 10.1080/10428194.2019.1612063.
    PubMed     Text format    


  67. SHIMAZU Y, Nohgawa M
    Plasma exchange following mogamulizumab therapy before bone marrow transplantation in refractory adult T-cell leukemia-lymphoma.
    Leuk Lymphoma. 2019 May 20:1-2. doi: 10.1080/10428194.2019.1616188.
    PubMed     Text format    


  68. PAIGE E, Haywood P, Xie M, Worth L, et al
    Auditing fungal disease in leukemia patients in a tertiary care center: opportunities and challenges for an antifungal stewardship program.
    Leuk Lymphoma. 2019 May 17:1-11. doi: 10.1080/10428194.2019.1590570.
    PubMed     Text format     Abstract available


  69. RAFEI H, Kantarjian HM, Jabbour EJ
    Recent advances in the treatment of acute lymphoblastic leukemia.
    Leuk Lymphoma. 2019 May 16:1-16. doi: 10.1080/10428194.2019.1605071.
    PubMed     Text format     Abstract available


  70. SOUMERAI JD, Davids MS, Werner L, Fisher DC, et al
    Phase 1 study of lenalidomide, bendamustine, and rituximab in previously untreated patients with chronic lymphocytic leukemia.
    Leuk Lymphoma. 2019 May 10:1-8. doi: 10.1080/10428194.2019.1608533.
    PubMed     Text format     Abstract available


  71. SALAMERO O, Martinez-Cuadron D, Sobas M, Benavente C, et al
    Real life outcomes of patients aged >/=75 years old with acute promyelocytic leukemia: experience of the PETHEMA registry.
    Leuk Lymphoma. 2019 May 9:1-13. doi: 10.1080/10428194.2019.1607327.
    PubMed     Text format     Abstract available


  72. KREITMAN RJ
    Hairy cell leukemia: present and future directions.
    Leuk Lymphoma. 2019 May 9:1-11. doi: 10.1080/10428194.2019.1608536.
    PubMed     Text format     Abstract available


  73. TAKEDA R, Yokoyama K, Ogawa M, Kawamata T, et al
    The first case of elderly TCF3-HLF-positive B-cell acute lymphoblastic leukemia.
    Leuk Lymphoma. 2019 May 6:1-4. doi: 10.1080/10428194.2019.1602267.
    PubMed     Text format    


  74. ZHANG X, Guo X
    Coexistence of BCR/ABL1 p190 transcript and CEBPA double mutations in de novo acute myeloid leukemia.
    Leuk Lymphoma. 2019 May 3:1-3. doi: 10.1080/10428194.2019.1608532.
    PubMed     Text format    


  75. DELLA STARZA I, De Novi LA, Santoro A, Salemi D, et al
    Digital droplet PCR and next-generation sequencing refine minimal residual disease monitoring in acute lymphoblastic leukemia.
    Leuk Lymphoma. 2019 May 3:1-3. doi: 10.1080/10428194.2019.1607325.
    PubMed     Text format    


  76. REFAEI M, Radhwi O, Sandhu I, Brandwein J, et al
    A strategy of Day14 bone marrows and early intervention is not superior to a strategy of noDay14 bone marrows and delayed intervention in patients with acute myeloid leukemia.
    Leuk Lymphoma. 2019 May 2:1-9. doi: 10.1080/10428194.2018.1543878.
    PubMed     Text format     Abstract available


    April 2019
  77. ZHANG X, Huang X, Xu H, Li J, et al
    MLL-rearrangement can resemble acute promyelocytic leukemia.
    Leuk Lymphoma. 2019 Apr 30:1-3. doi: 10.1080/10428194.2019.1607328.
    PubMed     Text format    


  78. GABELLI M, Disaro S, Scarparo P, Francescato S, et al
    Cerebrospinal fluid analysis by 8-color flow cytometry in children with acute lymphoblastic leukemia.
    Leuk Lymphoma. 2019 Apr 25:1-4. doi: 10.1080/10428194.2019.1602269.
    PubMed     Text format    


  79. XIE W, Chen Z, Wang SA, Hu S, et al
    Lymphoblastic leukemia following myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms.
    Leuk Lymphoma. 2019 Apr 24:1-9. doi: 10.1080/10428194.2019.1605509.
    PubMed     Text format     Abstract available


  80. BEZERRA ED, Flowers ME, Onstad LE, Chielens D, et al
    A phase 2 study of alpha interferon for molecularly measurable residual disease in chronic myeloid leukemia after allogeneic hematopoietic cell transplantation.
    Leuk Lymphoma. 2019 Apr 24:1-8. doi: 10.1080/10428194.2019.1605508.
    PubMed     Text format     Abstract available


  81. HAMPEL PJ, Ding W, Call TG, Rabe KG, et al
    Rapid disease progression following discontinuation of ibrutinib in patients with chronic lymphocytic leukemia treated in routine clinical practice.
    Leuk Lymphoma. 2019 Apr 24:1-8. doi: 10.1080/10428194.2019.1602268.
    PubMed     Text format     Abstract available


  82. ALDOSS I, Pullarkat V
    Response to single agent dasatinib post allogeneic transplant in B-cell acute lymphoblastic leukemia with NUP214-ABL1.
    Leuk Lymphoma. 2019 Apr 24:1-3. doi: 10.1080/10428194.2019.1605510.
    PubMed     Text format    


  83. TALLIS E, Loghavi S, Jorgensen JL, Wang S, et al
    Patient with mixed-phenotype acute leukemia with CBFB rearrangement.
    Leuk Lymphoma. 2019 Apr 23:1-3. doi: 10.1080/10428194.2019.1605069.
    PubMed     Text format    


  84. TOTH LN, Green D, Peterson J, Deharvengt SJ, et al
    Variant allele frequencies do not correlate well with myeloblast counts in a clinically validated gene sequencing panel for routine acute myeloid leukemia workup.
    Leuk Lymphoma. 2019 Apr 18:1-8. doi: 10.1080/10428194.2019.1587757.
    PubMed     Text format     Abstract available


  85. GOMEZ-ARTEAGA A, Margolskee E, Wei MT, van Besien K, et al
    Combined use of tofacitinib (pan-JAK inhibitor) and ruxolitinib (a JAK1/2 inhibitor) for refractory T-cell prolymphocytic leukemia (T-PLL) with a JAK3 mutation.
    Leuk Lymphoma. 2019 Apr 18:1-6. doi: 10.1080/10428194.2019.1594220.
    PubMed     Text format    


  86. FRAISON JB, Grignano E, Braun T, Ades L, et al
    Autoantibodies in myelodysplastic syndromes and chronic myelomonocytic leukemia.
    Leuk Lymphoma. 2019 Apr 8:1-3. doi: 10.1080/10428194.2019.1599114.
    PubMed     Text format    


  87. XU M, Liu H, Liu Y, Ma X, et al
    Gene mutations and pretransplant minimal residual disease predict risk of relapse in adult patients after allogeneic hematopoietic stem-cell transplantation for T cell acute lymphoblastic leukemia.
    Leuk Lymphoma. 2019 Apr 5:1-10. doi: 10.1080/10428194.2019.1597270.
    PubMed     Text format     Abstract available


  88. TSIROGIANNI M, Grigoriou E, Kapsimalli V, Dagla K, et al
    Natural killer cell cytotoxicity is a predictor of outcome for patients with high risk myelodysplastic syndrome and oligoblastic acute myeloid leukemia treated with azacytidine.
    Leuk Lymphoma. 2019 Apr 5:1-7. doi: 10.1080/10428194.2019.1581935.
    PubMed     Text format     Abstract available


  89. DOMBRET H, Topp MS, Schuh AC, Wei AH, et al
    Blinatumomab versus chemotherapy in first salvage or in later salvage for B-cell precursor acute lymphoblastic leukemia.
    Leuk Lymphoma. 2019 Apr 5:1-9. doi: 10.1080/10428194.2019.1576872.
    PubMed     Text format     Abstract available


  90. BEYAR-KATZ O, Lavi N, Ringelstein-Harlev S, Henig I, et al
    Superior outcome of patients with favorable-risk acute myeloid leukemia using consolidation with autologous stem cell transplantation.
    Leuk Lymphoma. 2019 Apr 3:1-8. doi: 10.1080/10428194.2019.1594214.
    PubMed     Text format     Abstract available


    March 2019
  91. DESHIELDS TL, Dueck AC, Rogers K, Brown JR, et al
    Perceived risk for cancer progression and psychological status in chronic lymphocytic leukemia patients: CALGB 70603 (Alliance).
    Leuk Lymphoma. 2019 Mar 27:1-4. doi: 10.1080/10428194.2019.1594218.
    PubMed     Text format    


  92. BERDEJA JG, Heinrich MC, Dakhil SR, Goldberg SL, et al
    Rates of deep molecular response by digital and conventional PCR with frontline nilotinib in newly diagnosed chronic myeloid leukemia: a landmark analysis.
    Leuk Lymphoma. 2019 Mar 26:1-10. doi: 10.1080/10428194.2019.1590569.
    PubMed     Text format     Abstract available


  93. BUCKLEY SA, Mark NM, Othus M, Estey EH, et al
    Diagnostic utility of bronchoscopy in adults with acute myeloid leukemia and other high-grade myeloid neoplasms.
    Leuk Lymphoma. 2019 Mar 11:1-4. doi: 10.1080/10428194.2019.1581933.
    PubMed     Text format    


  94. NAYMAGON L, Moshier E, Tremblay D, Mascarenhas J, et al
    Predictors of early hemorrhage in acute promyelocytic leukemia.
    Leuk Lymphoma. 2019 Mar 8:1-10. doi: 10.1080/10428194.2019.1581187.
    PubMed     Text format     Abstract available


    February 2019
  95. SALEHI S, Astle JM, Sadigh S, Lake J, et al
    Myeloid neoplasm with eosinophilia and PCM1-JAK2 associated with acute promyelocytic leukemia with PML-RARA.
    Leuk Lymphoma. 2019 Feb 26:1-5. doi: 10.1080/10428194.2019.1581927.
    PubMed     Text format    


  96. KONUMA T, Kato S, Oiwa-Monna M, Mizusawa M, et al
    Myeloablative single-unit cord blood transplantation overcomes the negative prognostic impact of FLT3-ITD in adult acute myeloid leukemia.
    Leuk Lymphoma. 2019 Feb 18:1-4. doi: 10.1080/10428194.2019.1579325.
    PubMed     Text format    


  97. PELLAND-MARCOTTE MC, Hwee J, Pole JD, Nathan PC, et al
    Incidence of infections after therapy completion in children with acute lymphoblastic leukemia or acute myeloid leukemia: a systematic review of the literature.
    Leuk Lymphoma. 2019 Feb 18:1-11. doi: 10.1080/10428194.2019.1573369.
    PubMed     Text format     Abstract available


  98. JAROSOVA M, Plevova K, Kotaskova J, Doubek M, et al
    The importance of complex karyotype in prognostication and treatment of chronic lymphocytic leukemia (CLL): a comprehensive review of the literature.
    Leuk Lymphoma. 2019 Feb 18:1-8. doi: 10.1080/10428194.2019.1576038.
    PubMed     Text format     Abstract available


  99. LAI TH, Mitchell S, Wu PJ, Orwick S, et al
    HSP90 inhibition depletes DNA repair proteins to sensitize acute myelogenous leukemia to nucleoside analog chemotherapeutics.
    Leuk Lymphoma. 2019 Feb 18:1-4. doi: 10.1080/10428194.2019.1571197.
    PubMed     Text format    


  100. PEROL L, Grignano E, Contejean A, Gastaud L, et al
    High-dose chemotherapy without transfusion for Philadelphia chromosome negative B-cell acute lymphoblastic leukemia in two Jehovah's Witnesses patients: a feasible option in the age of hematopoietic growth factors.
    Leuk Lymphoma. 2019 Feb 18:1-4. doi: 10.1080/10428194.2019.1577414.
    PubMed     Text format    


  101. DENG DX, Zhu HH, Liu YR, Chang YJ, et al
    Minimal residual disease detected by multiparameter flow cytometry is complementary to genetics for risk stratification treatment in acute myeloid leukemia with biallelic CEBPA mutations.
    Leuk Lymphoma. 2019 Feb 18:1-9. doi: 10.1080/10428194.2019.1576868.
    PubMed     Text format     Abstract available


  102. DAI K, Zhang Q, Li Y, Wu L, et al
    Plasma fibrinogen levels correlate with prognosis and treatment outcome in patients with non-M3 acute myeloid leukemia.
    Leuk Lymphoma. 2019 Feb 8:1-9. doi: 10.1080/10428194.2018.1535116.
    PubMed     Text format     Abstract available


  103. WINESTONE LE, Getz KD, Rao P, Li Y, et al
    Disparities in pediatric acute myeloid leukemia (AML) clinical trial enrollment.
    Leuk Lymphoma. 2019 Feb 7:1-9. doi: 10.1080/10428194.2019.1574002.
    PubMed     Text format     Abstract available


  104. BOSE P, Chen LS, Gandhi V
    Ibrutinib dose and clinical outcome in chronic lymphocytic leukemia - learning from the 'real world'.
    Leuk Lymphoma. 2019 Feb 6:1-3. doi: 10.1080/10428194.2019.1571207.
    PubMed     Text format    


  105. XU Y, Zhou X, Li Y, Zhang Y, et al
    Suppression of minichromosome maintenance 7 expression sensitizes chronic lymphocytic leukemia cells to fludarabine.
    Leuk Lymphoma. 2019 Feb 4:1-9. doi: 10.1080/10428194.2018.1523400.
    PubMed     Text format     Abstract available


  106. ZHANG J, Yang F, Qiu HY, Wu Q, et al
    Anti-CD19 chimeric antigen receptors T cells for the treatment of relapsed or refractory E2A-PBX1 positive acute lymphoblastic leukemia: report of three cases.
    Leuk Lymphoma. 2019 Feb 4:1-8. doi: 10.1080/10428194.2018.1533127.
    PubMed     Text format     Abstract available


  107. NATARAJAN H
    Plasma imatinib trough level measurements is still appropriate to predict therapeutic responses in patients with chronic myeloid leukemia.
    Leuk Lymphoma. 2019 Feb 4:1-2. doi: 10.1080/10428194.2019.1571206.
    PubMed     Text format    


  108. ESKAZAN AE
    Is measuring plasma imatinib trough levels still an appropriate way for predicting responses in patients with chronic myeloid leukemia?
    Leuk Lymphoma. 2019 Feb 4:1-2. doi: 10.1080/10428194.2019.1571202.
    PubMed     Text format    


    January 2019
  109. ARGYROU C, Hatziagapiou K, Theodorakidou M, Nikola OA, et al
    The role of adiponectin, LEPTIN, and ghrelin in the progress and prognosis of childhood acute lymphoblastic leukemia.
    Leuk Lymphoma. 2019 Jan 30:1-12. doi: 10.1080/10428194.2019.1569230.
    PubMed     Text format     Abstract available


  110. RITCHIE EK, Latremouille-Viau D, Guerin A, Pivneva I, et al
    Tyrosine kinase inhibitor therapy treatment and discontinuation in patients with chronic myeloid leukemia in chronic phase in the United States: a clinical practice perspective.
    Leuk Lymphoma. 2019 Jan 22:1-9. doi: 10.1080/10428194.2018.1538510.
    PubMed     Text format     Abstract available


  111. KHOT A
    Where do we currently stand with T-cell prolymphocytic leukemia?
    Leuk Lymphoma. 2019 Jan 22:1-3. doi: 10.1080/10428194.2018.1551543.
    PubMed     Text format    


  112. SHIPOUNOVA IN, Petinati NA, Bigildeev AE, Sorokina TV, et al
    Alterations in multipotent mesenchymal stromal cells from the bone marrow of acute myeloid leukemia patients at diagnosis and during treatment.
    Leuk Lymphoma. 2019 Jan 22:1-8. doi: 10.1080/10428194.2018.1554861.
    PubMed     Text format     Abstract available


  113. ECTOR GICG, Govers TM, Westerweel PE, Grutters JPC, et al
    The potential health gain and cost savings of improving adherence in chronic myeloid leukemia.
    Leuk Lymphoma. 2019 Jan 22:1-8. doi: 10.1080/10428194.2018.1535113.
    PubMed     Text format     Abstract available


  114. BEWERSDORF JP, Stahl M, Zeidan AM
    Are we witnessing the start of a therapeutic revolution in acute myeloid leukemia?
    Leuk Lymphoma. 2019 Jan 17:1-16. doi: 10.1080/10428194.2018.1546854.
    PubMed     Text format     Abstract available


  115. KERMEZLI Y, Saadi W, Belhocine M, Mathieu EL, et al
    A comprehensive catalog of LncRNAs expressed in T-cell acute lymphoblastic leukemia.
    Leuk Lymphoma. 2019 Jan 16:1-13. doi: 10.1080/10428194.2018.1551534.
    PubMed     Text format     Abstract available


  116. SHEN Y, Crassini K, Sandhu S, Fatima N, et al
    Dual inhibition of MEK1/2 and AKT by binimetinib and MK2206 induces apoptosis of chronic lymphocytic leukemia cells under conditions that mimic the tumor microenvironment.
    Leuk Lymphoma. 2019 Jan 16:1-12. doi: 10.1080/10428194.2018.1542148.
    PubMed     Text format     Abstract available


  117. QUINTAS-CARDAMA A
    CD19 directed CARs in acute lymphoblastic leukemia: state of the art and beyond.
    Leuk Lymphoma. 2019 Jan 16:1-3. doi: 10.1080/10428194.2018.1533132.
    PubMed     Text format    


  118. AWAN FT, Thirman MJ, Patel-Donnelly D, Assouline S, et al
    Entospletinib monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia previously treated with B-cell receptor inhibitors: results of a phase 2 study.
    Leuk Lymphoma. 2019 Jan 11:1-6. doi: 10.1080/10428194.2018.1562180.
    PubMed     Text format     Abstract available


  119. ZHANG X, Li F, Wang J, Suo S, et al
    RARgamma-rearrangements resemble acute promyelocytic leukemia and benefit from 3 + 7 regimen.
    Leuk Lymphoma. 2019 Jan 11:1-4. doi: 10.1080/10428194.2018.1553302.
    PubMed     Text format    


  120. ALBERTSEN BK, Harila-Saari A, Jahnukainen K, Lahteenmaki P, et al
    Asparaginase treatment in infants with acute lymphoblastic leukemia; pharmacokinetics and asparaginase hypersensitivity in Interfant-06.
    Leuk Lymphoma. 2019 Jan 11:1-7. doi: 10.1080/10428194.2018.1538507.
    PubMed     Text format     Abstract available


  121. LASICA M, Willcox A, Burbury K, Ross DM, et al
    The effect of tyrosine kinase inhibitor interruption and interferon use on pregnancy outcomes and long-term disease control in chronic myeloid leukemia.
    Leuk Lymphoma. 2019 Jan 11:1-7. doi: 10.1080/10428194.2018.1551533.
    PubMed     Text format     Abstract available


  122. BODDU P, Gibbons J, Burger J, Sivina M, et al
    Co-occurrence of chronic myeloid leukemia with chronic lymphocytic leukemia: a report of two cases.
    Leuk Lymphoma. 2019 Jan 11:1-4. doi: 10.1080/10428194.2018.1547902.
    PubMed     Text format    


  123. TEH BW, Chui W, Handunnetti S, Tam C, et al
    High rates of proven invasive fungal disease with the use of ibrutinib monotherapy for relapsed or refractory chronic lymphocytic leukemia.
    Leuk Lymphoma. 2019 Jan 11:1-4. doi: 10.1080/10428194.2018.1543884.
    PubMed     Text format    


  124. SADIGH S, Morrissette JJD, Bagg A
    FBXW7 mutations in acute myeloid leukemia.
    Leuk Lymphoma. 2019 Jan 11:1-2. doi: 10.1080/10428194.2018.1537488.
    PubMed     Text format    


  125. DANESE MD, Katz A, Cetin K, Chia V, et al
    Treatment patterns, survival, and hospitalization in adult patients with acute lymphoblastic leukemia: an observational cohort study using SEER Medicare data.
    Leuk Lymphoma. 2019 Jan 11:1-10. doi: 10.1080/10428194.2018.1555329.
    PubMed     Text format     Abstract available


  126. ESTEY E
    'Looking beyond survival to define therapeutic value in acute myeloid leukemia'.
    Leuk Lymphoma. 2019 Jan 10:1-3. doi: 10.1080/10428194.2018.1543886.
    PubMed     Text format    


  127. MA H, Padmanabhan Iyer S, Parmar S, Gong Y, et al
    Adoptive cell therapy for acute myeloid leukemia.
    Leuk Lymphoma. 2019 Jan 10:1-11. doi: 10.1080/10428194.2018.1553300.
    PubMed     Text format     Abstract available


  128. SCHORE RJ, Devidas M, Bleyer A, Reaman GH, et al
    Plasma asparaginase activity and asparagine depletion in acute lymphoblastic leukemia patients treated with pegaspargase on Children's Oncology Group AALL07P4().
    Leuk Lymphoma. 2019 Jan 10:1-9. doi: 10.1080/10428194.2018.1542146.
    PubMed     Text format     Abstract available


  129. WANG Q, Wan J, Zhang W, Hao S, et al
    MCL-1 or BCL-xL-dependent resistance to the BCL-2 antagonist (ABT-199) can be overcome by specific inhibitor as single agents and in combination with ABT-199 in acute myeloid leukemia cells.
    Leuk Lymphoma. 2019 Jan 10:1-11. doi: 10.1080/10428194.2018.1563694.
    PubMed     Text format     Abstract available


  130. CHAOUI D, Hacini M, Fitoussi O, Karlin L, et al
    Relapsed or refractory chronic lymphocytic leukemia retreated with rituximab in daily practice: final results of the PERLE study.
    Leuk Lymphoma. 2019 Jan 9:1-5. doi: 10.1080/10428194.2018.1533130.
    PubMed     Text format    


  131. FOURNIER E, Inchiappa L, Delattre C, Pignon JM, et al
    Increased risk of adverse acute myeloid leukemia after anti-CD19-targeted immunotherapies in KMT2A-rearranged acute lymphoblastic leukemia: a case report and review of the literature.
    Leuk Lymphoma. 2019 Jan 7:1-4. doi: 10.1080/10428194.2018.1562185.
    PubMed     Text format    


  132. AKHTAR OS, Attwood K, Lund I, Hare R, et al
    Dose reductions in ibrutinib therapy are not associated with inferior outcomes in patients with chronic lymphocytic leukemia (CLL).
    Leuk Lymphoma. 2019 Jan 2:1-6. doi: 10.1080/10428194.2018.1554862.
    PubMed     Text format     Abstract available


  133. KNORR KLB, Tallman MS
    LeukeMYC prognostication.
    Leuk Lymphoma. 2019;60:1-2.
    PubMed     Text format    


    December 2018
  134. AUTORE F, Chiusolo P, Sora F, Giammarco S, et al
    Reduction of hospitalization and transfusion support in patients with acute promyelocytic leukemia treated with arsenic trioxide plus all-trans retinoic acid compared to chemotherapy plus all-trans retinoic acid.
    Leuk Lymphoma. 2018 Dec 11:1-3. doi: 10.1080/10428194.2018.1522436.
    PubMed     Text format    


  135. LABRADOR J, Luno E, Vellenga E, Brunet S, et al
    Clinical significance of complex karyotype at diagnosis in pediatric and adult patients with de novo acute promyelocytic leukemia treated with ATRA and chemotherapy.
    Leuk Lymphoma. 2018 Dec 11:1-10. doi: 10.1080/10428194.2018.1522438.
    PubMed     Text format     Abstract available


  136. YAMAMOTO K, Yakushijin K, Ichikawa H, Okamura A, et al
    Coexpression of ETV6/MDS1/EVI1 and ETV6/EVI1 fusion transcripts in acute myeloid leukemia with t(3;12)(q26.2;p13) and thrombocytosis.
    Leuk Lymphoma. 2018 Dec 11:1-5. doi: 10.1080/10428194.2018.1529311.
    PubMed     Text format    


  137. MOLICA S, Giannarelli D, Mirabelli R, Levato L, et al
    The magnitude of improvement in progression-free survival with targeted therapy in relapsed/refractory chronic lymphocytic leukemia based on prognostic risk category: a systematic review and meta-analysis.
    Leuk Lymphoma. 2018 Dec 5:1-6. doi: 10.1080/10428194.2018.1543882.
    PubMed     Text format     Abstract available


  138. KIM S, Freeland-Graves JH, Babaei M, Sachdev PK, et al
    Quantifying the association between acute leukemia and serum zinc, copper, and selenium: a meta-analysis.
    Leuk Lymphoma. 2018 Dec 5:1-9. doi: 10.1080/10428194.2018.1540043.
    PubMed     Text format     Abstract available


  139. JIANG X, Cheng Y, Hu C, Zhang A, et al
    MicroRNA-221 sensitizes chronic myeloid leukemia cells to imatinib by targeting STAT5.
    Leuk Lymphoma. 2018 Dec 5:1-12. doi: 10.1080/10428194.2018.1543875.
    PubMed     Text format     Abstract available


  140. OCK CY, Seo H, Kim DY, Min BJ, et al
    Discovery of donor genotype associated with long-term survival of patients with hematopoietic stem cell transplantation in refractory acute myeloid leukemia.
    Leuk Lymphoma. 2018 Dec 3:1-7. doi: 10.1080/10428194.2018.1542142.
    PubMed     Text format     Abstract available


  141. MICHAILOV Y, Lunenfeld E, Kapelushnik J, Huleihel M, et al
    Leukemia and male infertility: past, present, and future.
    Leuk Lymphoma. 2018 Dec 3:1-10. doi: 10.1080/10428194.2018.1533126.
    PubMed     Text format     Abstract available


    November 2018
  142. NAMN Y, Furman RR, Crawford C
    A rare colonic manifestation of chronic lymphocytic leukemia.
    Leuk Lymphoma. 2018 Nov 29:1-4. doi: 10.1080/10428194.2018.1459612.
    PubMed     Text format    


  143. SUN Y, Murty VV, Leeman-Neill R, Soderquist C, et al
    Cytogenetic analysis of adult T-Cell leukemia/lymphoma: evaluation of a Caribbean cohort.
    Leuk Lymphoma. 2018 Nov 27:1-3. doi: 10.1080/10428194.2018.1538506.
    PubMed     Text format    


  144. HARADA K, Yanada M, Machida S, Kanamori H, et al
    Prognostic impact of melphalan dose and total body irradiation use in patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation with reduced-intensity conditioning.
    Leuk Lymphoma. 2018 Nov 20:1-10. doi: 10.1080/10428194.2018.1535115.
    PubMed     Text format     Abstract available


  145. DIAMANTOPOULOS PT, Kotsianidis I, Symeonidis A, Pappa V, et al
    Chronic myelomonocytic leukemia treated with 5-azacytidine - results from the Hellenic 5-Azacytidine Registry: proposal of a new risk stratification system.
    Leuk Lymphoma. 2018 Nov 14:1-10. doi: 10.1080/10428194.2018.1540783.
    PubMed     Text format     Abstract available


  146. SOUMERAI JD, Ni A, Xing G, Huang J, et al
    Evaluation of the CLL-IPI in relapsed and refractory chronic lymphocytic leukemia in idelalisib phase-3 trials.
    Leuk Lymphoma. 2018 Nov 8:1-9. doi: 10.1080/10428194.2018.1540782.
    PubMed     Text format     Abstract available


  147. GURU MURTHY GS, Pondaiah SK, Abedin S, Atallah E, et al
    Incidence and survival of T-cell acute lymphoblastic leukemia in the United States.
    Leuk Lymphoma. 2018 Nov 8:1-8. doi: 10.1080/10428194.2018.1522442.
    PubMed     Text format     Abstract available


  148. NABHAN C, Kamat S, Karl Kish J
    Acute myeloid leukemia in the elderly: what constitutes treatment value?
    Leuk Lymphoma. 2018 Nov 8:1-7. doi: 10.1080/10428194.2018.1520992.
    PubMed     Text format     Abstract available


  149. RODRIGUEZ CM, Bussi C, Arroyo DS, Sastre D, et al
    Effects of rapamycin in combination with fludarabine on primary chronic lymphocytic leukemia cells.
    Leuk Lymphoma. 2018 Nov 8:1-5. doi: 10.1080/10428194.2018.1529309.
    PubMed     Text format    


  150. TAO S, Wang C, Chen Y, Deng Y, et al
    Long-term effect of all-trans retinoic acid and arsenic trioxide sequential maintenance in patients with acute promyelocytic leukemia.
    Leuk Lymphoma. 2018 Nov 8:1-9. doi: 10.1080/10428194.2018.1504941.
    PubMed     Text format     Abstract available


  151. ZAJAC-SPYCHALA O, Wachowiak J, Szmydki-Baran A, Hutnik L, et al
    Infectious complications in children treated for hodgkin and non-hodgkin lymphomas in polish pediatric leukemia/lymphoma study group: incidence, epidemiology and etiology.
    Leuk Lymphoma. 2018 Nov 5:1-9. doi: 10.1080/10428194.2018.1466293.
    PubMed     Text format     Abstract available


    October 2018
  152. POPP HD, Flach J, Brendel S, Ruppenthal S, et al
    Accumulation of DNA damage and alteration of the DNA damage response in monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia.
    Leuk Lymphoma. 2018 Oct 31:1-10. doi: 10.1080/10428194.2018.1498494.
    PubMed     Text format     Abstract available


  153. ZHANG S, Zhou W, Li Y, Yu S, et al
    Co-expression of AML1-ETO and PML-RARa following treatment of de novo acute myeloid leukemia with AML1-ETO.
    Leuk Lymphoma. 2018 Oct 17:1-4. doi: 10.1080/10428194.2018.1520991.
    PubMed     Text format    


  154. CHEN J, Ngo D, Aldoss I, Shayani S, et al
    Antithrombin supplementation did not impact the incidence of pegylated asparaginase-induced venous thromboembolism in adults with acute lymphoblastic leukemia.
    Leuk Lymphoma. 2018 Oct 15:1-6. doi: 10.1080/10428194.2018.1519811.
    PubMed     Text format     Abstract available


  155. BHANGOO MS, Saven A
    Secondary malignancies after treatment with single-agent vemurafenib in two patients with refractory hairy cell leukemia.
    Leuk Lymphoma. 2018 Oct 15:1-3. doi: 10.1080/10428194.2018.1519809.
    PubMed     Text format    


  156. SOBAS M, Montesinos P, Boluda B, Bernal T, et al
    An analysis of the impact of CD56 expression in de novo acute promyelocytic leukemia patients treated with upfront all-trans retinoic acid and anthracycline-based regimens.
    Leuk Lymphoma. 2018 Oct 15:1-6. doi: 10.1080/10428194.2018.1516875.
    PubMed     Text format     Abstract available


  157. DAVIDS MS, Kim HT, Yu L, De Maeyer G, et al
    Ofatumumab plus high dose methylprednisolone followed by ofatumumab plus alemtuzumab to achieve maximal cytoreduction prior to allogeneic transplantation for 17p deleted or TP53 mutated chronic lymphocytic leukemia.
    Leuk Lymphoma. 2018 Oct 15:1-4. doi: 10.1080/10428194.2018.1519814.
    PubMed     Text format     Abstract available


  158. MEI C, Ren Y, Zhou X, Ye L, et al
    Clinical and biological characteristics of acute myeloid leukemia with 20-29% blasts: a retrospective single-center study.
    Leuk Lymphoma. 2018 Oct 10:1-10. doi: 10.1080/10428194.2018.1515938.
    PubMed     Text format     Abstract available


  159. MOLICA S, Giannarelli D, Levato L, Mirabelli R, et al
    A simple score based on geriatric assessment predicts survival in elderly newly diagnosed chronic lymphocytic leukemia patients.
    Leuk Lymphoma. 2018 Oct 2:1-3. doi: 10.1080/10428194.2018.1508674.
    PubMed     Text format    


  160. NIEBOROWSKA-SKORSKA M, Maifrede S, Ye M, Toma M, et al
    Non-NAD-like PARP1 inhibitor enhanced synthetic lethal effect of NAD-like PARP inhibitors against BRCA1-deficient leukemia.
    Leuk Lymphoma. 2018 Oct 2:1-4. doi: 10.1080/10428194.2018.1520988.
    PubMed     Text format    


  161. CHEN X, Wang F, Zhang Y, Wang M, et al
    Panoramic view of common fusion genes in a large cohort of Chinese de novo acute myeloid leukemia patients.
    Leuk Lymphoma. 2018 Oct 2:1-8. doi: 10.1080/10428194.2018.1516876.
    PubMed     Text format     Abstract available


  162. BUCKLEY SA, Percival ME, Othus M, Halpern AB, et al
    A comparison of patients with acute myeloid leukemia and high-risk myelodysplastic syndrome treated on versus off study.
    Leuk Lymphoma. 2018 Oct 2:1-7. doi: 10.1080/10428194.2018.1516036.
    PubMed     Text format     Abstract available


  163. MILLER KC, Al-Kali A, Shah MV, Hogan WJ, et al
    Elderly acute lymphoblastic leukemia: a Mayo Clinic study of 124 patients.
    Leuk Lymphoma. 2018 Oct 2:1-10. doi: 10.1080/10428194.2018.1509318.
    PubMed     Text format     Abstract available


  164. WESTHUS J, Noppeney R, Duhrsen U, Hanoun M, et al
    FLAG salvage therapy combined with idarubicin in relapsed/refractory acute myeloid leukemia.
    Leuk Lymphoma. 2018 Oct 2:1-9. doi: 10.1080/10428194.2018.1508670.
    PubMed     Text format     Abstract available


  165. BARRIENTOS JC, Burger JA, Byrd JC, Hillmen P, et al
    Characterizing the kinetics of lymphocytosis in patients with chronic lymphocytic leukemia treated with single-agent ibrutinib.
    Leuk Lymphoma. 2018 Oct 2:1-6. doi: 10.1080/10428194.2018.1512710.
    PubMed     Text format     Abstract available


  166. SHETH V, Nachmias B, Grisariu S, Avni B, et al
    Augmented myeloablative conditioning with thiotepa in acute myeloid leukemia - improved outcomes with similar toxicity.
    Leuk Lymphoma. 2018 Oct 2:1-8. doi: 10.1080/10428194.2018.1510495.
    PubMed     Text format     Abstract available


  167. CHEN CI, Paul H, Snitzler S, Kakar S, et al
    A phase 2 study of lenalidomide and dexamethasone in previously untreated patients with chronic lymphocytic leukemia (CLL).
    Leuk Lymphoma. 2018 Oct 2:1-10. doi: 10.1080/10428194.2018.1508669.
    PubMed     Text format     Abstract available


  168. ROSSOFF J, Akpan I, Platanias LC
    Spontaneous remission in congenital leukemia.
    Leuk Lymphoma. 2018;59:2271-2272.
    PubMed     Text format    


    September 2018
  169. D'ARENA G, Seneca E, Migliaccio I, De Feo V, et al
    Oxidative stress in chronic lymphocytic leukemia: still a matter of debate.
    Leuk Lymphoma. 2018 Sep 20:1-9. doi: 10.1080/10428194.2018.1509317.
    PubMed     Text format     Abstract available


  170. MCMAHON CM, Perl AE
    Management of primary refractory acute myeloid leukemia in the era of targeted therapies.
    Leuk Lymphoma. 2018 Sep 20:1-14. doi: 10.1080/10428194.2018.1504937.
    PubMed     Text format     Abstract available


  171. EREN R, Karismaz A, Karatas D, Dogu MH, et al
    Comparison of clinical features and survival between young and old chronic lymphocytic leukemia patients: a single center study from Turkey.
    Leuk Lymphoma. 2018 Sep 6:1-6. doi: 10.1080/10428194.2018.1509316.
    PubMed     Text format     Abstract available


  172. SAENZ-DE-VITERI M, Cudrnak T
    Bilateral cystoid macular edema in a patient with chronic lymphocytic leukemia treated with ibrutinib.
    Leuk Lymphoma. 2018 Sep 6:1-3. doi: 10.1080/10428194.2018.1508673.
    PubMed     Text format    


  173. FERREIRA LAM, Capannacci J, Hokama NK, Nogueira CR, et al
    Circulating microRNAs expression profile in newly diagnosed and imatinib treated chronic phase - chronic myeloid leukemia.
    Leuk Lymphoma. 2018 Sep 6:1-7. doi: 10.1080/10428194.2018.1499905.
    PubMed     Text format     Abstract available


  174. GIANFELICI V, Messina M, Paoloni F, Peragine N, et al
    IL7R overexpression in adult acute lymphoblastic leukemia is associated to JAK/STAT pathway mutations and identifies patients who could benefit from targeted therapies.
    Leuk Lymphoma. 2018 Sep 6:1-4. doi: 10.1080/10428194.2018.1499906.
    PubMed     Text format    


  175. KNEZ V, Liu X, Schowinsky J, Pan Z, et al
    Clinicopathologic and genetic spectrum of infantile B-lymphoblastic leukemia: a multi-institutional study.
    Leuk Lymphoma. 2018 Sep 6:1-8. doi: 10.1080/10428194.2018.1508667.
    PubMed     Text format     Abstract available


  176. HE C, Luo B, Jiang N, Liang Y, et al
    OncomiR or antioncomiR: Role of miRNAs in Acute Myeloid Leukemia.
    Leuk Lymphoma. 2018 Sep 6:1-12. doi: 10.1080/10428194.2018.1480769.
    PubMed     Text format     Abstract available


  177. KUTTIKRISHNAN S, Siveen KS, Prabhu KS, Khan AQ, et al
    Sanguinarine suppresses growth and induces apoptosis in childhood acute lymphoblastic leukemia.
    Leuk Lymphoma. 2018 Sep 6:1-13. doi: 10.1080/10428194.2018.1494270.
    PubMed     Text format     Abstract available


  178. MAZHARUDDIN S, Chattopadhyay A, Levy MY, Redner RL, et al
    IRF2BP2-RARA t(1;17)(q42.3;q21.2) APL blasts differentiate in response to all-trans retinoic acid.
    Leuk Lymphoma. 2018;59:2246-2249.
    PubMed     Text format    


  179. LAMBA JK, Voigt AP, Chauhan L, Shin M, et al
    CD33 splicing SNP regulates expression levels of CD33 in normal regenerating monocytes in AML patients.
    Leuk Lymphoma. 2018;59:2250-2253.
    PubMed     Text format    


  180. KOMMALAPATI A, Kushchayeva Y, Tella SH
    Incidence, racial disparities and survival outcomes of mast cell malignancies: analysis from a national database.
    Leuk Lymphoma. 2018;59:2254-2257.
    PubMed     Text format    


  181. OO ZM, Illendula A, Grembecka J, Schmidt C, et al
    A tool compound targeting the core binding factor Runt domain to disrupt binding to CBFbeta in leukemic cells.
    Leuk Lymphoma. 2018;59:2188-2200.
    PubMed     Text format     Abstract available


    August 2018
  182. BORLENGHI E, Cattaneo C, Schieppati F, Gramegna D, et al
    Acute promyelocytic leukemia in patients aged >70 years is not rare and highly curable: a single center series of 21 unselected patients.
    Leuk Lymphoma. 2018 Aug 30:1-4. doi: 10.1080/10428194.2018.1492126.
    PubMed     Text format    


  183. CAO M, Carrasco RD, Dubuc AM, Dal Cin P, et al
    ZMYM2-FGFR1 fusion as secondary change in acute myeloid leukemia.
    Leuk Lymphoma. 2018 Aug 30:1-3. doi: 10.1080/10428194.2018.1493733.
    PubMed     Text format    


  184. SPEZIALI C, Daly A, Abuhaleeqa M, Nitta J, et al
    Fludarabine, busulfan, and low-dose TBI conditioning versus cyclophosphamide and TBI in allogeneic hematopoietic cell transplantation for adult acute lymphoblastic leukemia.
    Leuk Lymphoma. 2018 Aug 30:1-10. doi: 10.1080/10428194.2018.1493734.
    PubMed     Text format     Abstract available


  185. JABBOUR EJ, Siegartel LR, Lin J, Lingohr-Smith M, et al
    Impact of earlier versus later monitoring on disease progression and healthcare costs among patients with chronic myeloid leukemia in the United States.
    Leuk Lymphoma. 2018 Aug 20:1-7. doi: 10.1080/10428194.2018.1492124.
    PubMed     Text format     Abstract available


  186. NATARAJAN H, Kumar L, Bakhshi S, Sharma A, et al
    Imatinib trough levels: a potential biomarker to predict cytogenetic and molecular response in newly diagnosed patients with chronic myeloid leukemia.
    Leuk Lymphoma. 2018 Aug 20:1-8. doi: 10.1080/10428194.2018.1485907.
    PubMed     Text format     Abstract available


  187. OLSHANSKAYA Y, Kazakova A, Tsaur G, Zerkalenkova E, et al
    Clinical significance of cytogenetic changes in childhood T-cell acute lymphoblastic leukemia: results of the multicenter group Moscow-Berlin (MB).
    Leuk Lymphoma. 2018 Aug 1:1-7. doi: 10.1080/10428194.2018.1485904.
    PubMed     Text format     Abstract available


  188. WALZ JS, Kowalewski DJ, Backert L, Nelde A, et al
    Favorable immune signature in CLL patients, defined by antigen-specific T-cell responses, might prevent second skin cancers.
    Leuk Lymphoma. 2018;59:1949-1958.
    PubMed     Text format     Abstract available


  189. MA J, Dunlap J, Paliga A, Traer E, et al
    DNMT3A co-mutation is required for FLT3-ITD as an adverse prognostic indicator in intermediate-risk cytogenetic group AML.
    Leuk Lymphoma. 2018;59:1938-1948.
    PubMed     Text format     Abstract available


  190. SHEN Y, Best OG, Mulligan SP, Christopherson RI, et al
    Ibrutinib and idelalisib block immunophenotypic changes associated with the adhesion and activation of CLL cells in the tumor microenvironment.
    Leuk Lymphoma. 2018;59:1927-1937.
    PubMed     Text format     Abstract available


  191. AW A, Kim HT, Fernandes SM, Hoang K, et al
    Minimal residual disease detected by immunoglobulin sequencing predicts CLL relapse more effectively than flow cytometry.
    Leuk Lymphoma. 2018;59:1986-1989.
    PubMed     Text format    


    July 2018
  192. XU YP, Wieten L, Wang SX, Cai Y, et al
    Clinical significance of HLA-E genotype and surface/soluble expression levels between healthy individuals and patients with acute leukemia.
    Leuk Lymphoma. 2018 Jul 3:1-8. doi: 10.1080/10428194.2018.1474521.
    PubMed     Text format     Abstract available


  193. CHELLAPANDIAN D, Pole JD, Nathan PC, Sung L, et al
    Congestive heart failure among children with acute leukemia: a population-based matched cohort study.
    Leuk Lymphoma. 2018 Jul 3:1-10. doi: 10.1080/10428194.2018.1474522.
    PubMed     Text format     Abstract available


  194. KAIFIE A, Schikowsky C, Vasko T, Kraus T, et al
    Additional benefits of telomere length (TL) measurements in chronic lymphocytic leukemia.
    Leuk Lymphoma. 2018 Jul 3:1-3. doi: 10.1080/10428194.2018.1482544.
    PubMed     Text format    


  195. KATHIRAVAN M, Singh M, Bhatia P, Trehan A, et al
    Deletion of CDKN2A/B is associated with inferior relapse free survival in pediatric B cell acute lymphoblastic leukemia.
    Leuk Lymphoma. 2018 Jul 3:1-9. doi: 10.1080/10428194.2018.1482542.
    PubMed     Text format     Abstract available


  196. JURCZYSZYN A, Castillo JJ, Avivi I, Czepiel J, et al
    Secondary plasma cell leukemia: a multicenter retrospective study of 101 patients.
    Leuk Lymphoma. 2018 Jul 2:1-6. doi: 10.1080/10428194.2018.1473574.
    PubMed     Text format     Abstract available


  197. ERBILGIN Y, Eskazan AE, Hatirnaz Ng O, Salihoglu A, et al
    Deep sequencing of BCR-ABL1 kinase domain mutations in chronic myeloid leukemia patients with resistance to tyrosine kinase inhibitors.
    Leuk Lymphoma. 2018 Jul 2:1-9. doi: 10.1080/10428194.2018.1473573.
    PubMed     Text format     Abstract available


  198. STAHL M, DeVeaux M, Montesinos P, Itzykson R, et al
    Performance of the Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) score in predicting survival benefit with hypomethylating agent use in patients with relapsed or refractory acute myeloid leukemia.
    Leuk Lymphoma. 2018 Jul 2:1-4. doi: 10.1080/10428194.2018.1468893.
    PubMed     Text format    


  199. LOZANO C, Brun S, Arnaud A, Gaulard P, et al
    Complete remission of agranulocytosis after splenectomy in a variant form of T-cell large granular lymphocyte leukemia.
    Leuk Lymphoma. 2018 Jul 2:1-4. doi: 10.1080/10428194.2018.1471601.
    PubMed     Text format    


  200. SAGLIO G, Jabbour E
    First-line therapy for chronic phase CML: selecting the optimal BCR-ABL1-targeted TKI.
    Leuk Lymphoma. 2018;59:1523-1538.
    PubMed     Text format     Abstract available


  201. TANG CPS, McMullen J, Tam C
    Cardiac side effects of bruton tyrosine kinase (BTK) inhibitors.
    Leuk Lymphoma. 2018;59:1554-1564.
    PubMed     Text format     Abstract available


  202. STRATI P, Tang G, Duose DY, Mallampati S, et al
    Myeloid/lymphoid neoplasms with FGFR1 rearrangement.
    Leuk Lymphoma. 2018;59:1672-1676.
    PubMed     Text format     Abstract available


  203. DASGUPTA Y, Golovine K, Nieborowska-Skorska M, Luo L, et al
    Drugging DNA repair to target T-ALL cells.
    Leuk Lymphoma. 2018;59:1746-1749.
    PubMed     Text format    


  204. BURKE MJ, Devidas M, Maloney K, Angiolillo A, et al
    Severe pegaspargase hypersensitivity reaction rates (grade >/=3) with intravenous infusion vs. intramuscular injection: analysis of 54,280 doses administered to 16,534 patients on children's oncology group (COG) clinical trials.
    Leuk Lymphoma. 2018;59:1624-1633.
    PubMed     Text format     Abstract available


  205. VAKHARIA P, Nardone B, Budris W, Hoshizaki K, et al
    Blinatumomab and pancreatitis: an analysis of FAERS, EudraVigilance, and a large urban U.S. patient population data.
    Leuk Lymphoma. 2018;59:1759-1761.
    PubMed     Text format    


    June 2018
  206. CAPRIA S, Pepe S, Trisolini SM, Testi AM, et al
    Autologous stem cell transplant in acute lymphoblastic leukemia: prognostic impact of pre-transplant minimal residual disease.
    Leuk Lymphoma. 2018 Jun 26:1-3. doi: 10.1080/10428194.2018.1468895.
    PubMed     Text format    


  207. PODSZYWALOW-BARTNICKA P, Maifrede S, Le BV, Nieborowska-Skorska M, et al
    PARP1 inhibitor eliminated imatinib-refractory chronic myeloid leukemia cells in bone marrow microenvironment conditions.
    Leuk Lymphoma. 2018 Jun 22:1-3. doi: 10.1080/10428194.2018.1471602.
    PubMed     Text format    


  208. CHEN CI, Paul H, Le LW, Wei EN, et al
    A phase 2 study of ofatumumab (Arzerra((R))) in combination with a pan-AKT inhibitor (afuresertib) in previously treated patients with chronic lymphocytic leukemia (CLL).
    Leuk Lymphoma. 2018 Jun 19:1-9. doi: 10.1080/10428194.2018.1468892.
    PubMed     Text format     Abstract available


  209. THAN H, Lye WK, Sng C, Allen JC Jr, et al
    BIM deletion polymorphism profiling complements prognostic values of risk scores in imatinib-treated Asian chronic myeloid leukemia patients.
    Leuk Lymphoma. 2018 Jun 19:1-4. doi: 10.1080/10428194.2018.1461863.
    PubMed     Text format    


  210. CRASSINI K, Pyke T, Shen Y, Stevenson WS, et al
    Inhibition of the Raf-1 kinase inhibitory protein (RKIP) by locostatin induces cell death and reduces the CXCR4-mediated migration of chronic lymphocytic leukemia cells.
    Leuk Lymphoma. 2018 Jun 18:1-12. doi: 10.1080/10428194.2018.1455974.
    PubMed     Text format     Abstract available


  211. STRATI P, Gabutti C, Thompson PA, Kontoyiannis DP, et al
    Cytomegalovirus reactivation can be a cause of DAT-negative hemolytic anemia in patients with chronic lymphocytic leukemia.
    Leuk Lymphoma. 2018 Jun 18:1-3. doi: 10.1080/10428194.2018.1474527.
    PubMed     Text format    


  212. PAPAGEORGIOU SG, Diamantopoulos MA, Kontos CK, Bouchla A, et al
    MicroRNA-92a-3p overexpression in peripheral blood mononuclear cells is an independent predictor of prolonged overall survival of patients with chronic lymphocytic leukemia.
    Leuk Lymphoma. 2018 Jun 18:1-10. doi: 10.1080/10428194.2018.1461861.
    PubMed     Text format     Abstract available


  213. YAMAMOTO K, Yakushijin K, Ichikawa H, Kakiuchi S, et al
    Expression of a novel ZMYND11/MBTD1 fusion transcript in CD7(+)CD56(+) acute myeloid leukemia with t(10;17)(p15;q21).
    Leuk Lymphoma. 2018 Jun 18:1-5. doi: 10.1080/10428194.2018.1464157.
    PubMed     Text format    


  214. BERTOLI S, Tavitian S, Berard E, Gadaud N, et al
    Outcome of relapsed or refractory acute myeloid leukemia treated with intensive salvage chemotherapy in real life in comparison to intermediate dose cytarabine in phase 3 studies.
    Leuk Lymphoma. 2018 Jun 12:1-4. doi: 10.1080/10428194.2018.1464156.
    PubMed     Text format    


  215. HIWASE D, Ross D
    Success is built on failures: tackling the challenge of ponatinib failure.
    Leuk Lymphoma. 2018;59:1279-1281.
    PubMed     Text format    


  216. BODDU P, Shah AR, Borthakur G, Verstovsek S, et al
    Life after ponatinib failure: outcomes of chronic and accelerated phase CML patients who discontinued ponatinib in the salvage setting.
    Leuk Lymphoma. 2018;59:1312-1322.
    PubMed     Text format     Abstract available


  217. BODDU P, Oviedo SP, Rausch CR, Yam C, et al
    PET-CT in AML-related hemophagocytic lymphohistiocytosis.
    Leuk Lymphoma. 2018;59:1486-1489.
    PubMed     Text format    


    May 2018
  218. PLEYER C, Wiestner A, Sun C
    Immunological changes with kinase inhibitor therapy for chronic lymphocytic leukemia.
    Leuk Lymphoma. 2018 May 15:1-9. doi: 10.1080/10428194.2018.1457147.
    PubMed     Text format     Abstract available


  219. YOGARAJAH M, Montgomery N, Matson M, Blanchard L, et al
    Clonal evolution of Philadelphia chromosome in acute myeloid leukemia after azacitidine treatment.
    Leuk Lymphoma. 2018 May 11:1-3. doi: 10.1080/10428194.2018.1459614.
    PubMed     Text format    


  220. OHANIAN M, Rozovski U, Kanagal-Shamanna R, Abruzzo LV, et al
    MYC protein expression is an important prognostic factor in acute myeloid leukemia.
    Leuk Lymphoma. 2018 May 9:1-12. doi: 10.1080/10428194.2018.1464158.
    PubMed     Text format     Abstract available


  221. KRULL K, Kunstreich M, Bronsema A, Bleckmann K, et al
    Osteonecrosis in children with acute lymphoblastic leukemia at initial diagnosis and prior to any chemotherapy.
    Leuk Lymphoma. 2018 May 2:1-7. doi: 10.1080/10428194.2018.1466292.
    PubMed     Text format     Abstract available


  222. LICATA MJ, Janakiram M, Tan S, Fang Y, et al
    Diagnostic challenges of adult T-cell leukemia/lymphoma in North America - a clinical, histological, and immunophenotypic correlation with a workflow proposal.
    Leuk Lymphoma. 2018;59:1188-1194.
    PubMed     Text format     Abstract available


  223. SATO E, Iriyama N, Tokuhira M, Takaku T, et al
    Introduction of second-generation tyrosine kinase inhibitors may reduce the prognostic impact of high-risk patients, according to the European treatment and outcome study (EUTOS) score.
    Leuk Lymphoma. 2018;59:1105-1112.
    PubMed     Text format     Abstract available


    April 2018
  224. STAHL M, Pine A, Hendrickson JE, Litzow MR, et al
    Beliefs and practice patterns in hyperleukocytosis management in acute myeloid leukemia: a large U.S. web-based survey().
    Leuk Lymphoma. 2018 Apr 18:1-4. doi: 10.1080/10428194.2018.1452219.
    PubMed     Text format    


  225. TAKEI T, Yokoyama K, Shimizu E, Konuma T, et al
    Azacitidine effectively reduces TP53-mutant leukemic cell burden in secondary acute myeloid leukemia after cord blood transplantation.
    Leuk Lymphoma. 2018 Apr 12:1-2. doi: 10.1080/10428194.2018.1443335.
    PubMed     Text format    


  226. REDNER RL, Beumer JH, Kropf P, Agha M, et al
    A phase-1 study of dasatinib plus all-trans retinoic acid in acute myeloid leukemia.
    Leuk Lymphoma. 2018 Apr 4:1-7. doi: 10.1080/10428194.2018.1443330.
    PubMed     Text format     Abstract available


  227. OJAMIES PN, Kontro M, Edgren H, Ellonen P, et al
    Case studies investigating genetic heterogeneity between anatomically distinct bone marrow compartments in acute myeloid leukemia.
    Leuk Lymphoma. 2018 Apr 4:1-4. doi: 10.1080/10428194.2018.1453067.
    PubMed     Text format    


  228. ZHANG H, Liang Z, Hu Y, Wang X, et al
    The effectiveness of interferon-alpha combined with imatinib in patient with chronic myeloid leukemia harboring T315I BCR-ABL1 mutation.
    Leuk Lymphoma. 2018 Apr 4:1-2. doi: 10.1080/10428194.2018.1443329.
    PubMed     Text format    


  229. VAN DER STRATEN L, Dinmohamed AG, Westerweel PE, Langerak AW, et al
    Rituximab addition to chemotherapy in real world patients with chronic lymphocytic leukemia: effective in first line but indication of lack of efficacy in subsequent lines of therapy.
    Leuk Lymphoma. 2018 Apr 4:1-5. doi: 10.1080/10428194.2018.1452215.
    PubMed     Text format    


  230. IMAGAWA J
    Switching from all-trans retinoic acid to arsenic trioxide for newly diagnosed acute promyelocytic leukemia.
    Leuk Lymphoma. 2018 Apr 4:1-3. doi: 10.1080/10428194.2018.1443333.
    PubMed     Text format    


  231. KUROSAWA S, Toya T, Kishida Y, Nagata A, et al
    Outcome of patients with acute undifferentiated leukemia after allogeneic hematopoietic stem cell transplantation.
    Leuk Lymphoma. 2018 Apr 4:1-4. doi: 10.1080/10428194.2018.1441410.
    PubMed     Text format    


  232. HUANG J, Hong M, Zhu Y, Zhao H, et al
    Decitabine in combination with G-CSF, low-dose cytarabine and aclarubicin is as effective as standard dose chemotherapy in the induction treatment for patients aged from 55 to 69 years old with newly diagnosed acute myeloid leukemia.
    Leuk Lymphoma. 2018 Apr 4:1-10. doi: 10.1080/10428194.2018.1443328.
    PubMed     Text format     Abstract available


  233. BODDU P, Kantarjian H, Garcia-Manero G, Allison J, et al
    The emerging role of immune checkpoint based approaches in AML and MDS.
    Leuk Lymphoma. 2018;59:790-802.
    PubMed     Text format     Abstract available


    March 2018
  234. HOVERSTEN K, Vallapureddy R, Lasho T, Finke C, et al
    Nonhepatosplenic extramedullary manifestations of chronic myelomonocytic leukemia: clinical, molecular and prognostic correlates.
    Leuk Lymphoma. 2018 Mar 27:1-4. doi: 10.1080/10428194.2018.1452212.
    PubMed     Text format    


  235. MACDONALD RJ, Bunaciu RP, Ip V, Dai D, et al
    Src family kinase inhibitor bosutinib enhances retinoic acid-induced differentiation of HL-60 leukemia cells.
    Leuk Lymphoma. 2018 Mar 23:1-11. doi: 10.1080/10428194.2018.1452213.
    PubMed     Text format     Abstract available


  236. SORIGUE M, Orna E, Sancho JM
    Venous thromboembolism in patients with non-Hodgkin lymphoma or chronic lymphocytic leukemia treated with lenalidomide: a systematic review.
    Leuk Lymphoma. 2018 Mar 21:1-10. doi: 10.1080/10428194.2018.1448085.
    PubMed     Text format     Abstract available


  237. PRESS KR, Uy N, Keefer J, Gore SD, et al
    Clinical evaluation of combined azacitidine and entinostat on the induction of fetal hemoglobin in patients with acute myeloid leukemias and myelodysplastic syndromes.
    Leuk Lymphoma. 2018;59:755-757.
    PubMed     Text format    


  238. HIRAI M, Yagasaki H, Fujimura J, Inoue M, et al
    Successful preemptive donor lymphocyte infusions from a haploidentical donor in a boy with E2A-HLF-positive ALL.
    Leuk Lymphoma. 2018;59:746-748.
    PubMed     Text format    


    February 2018
  239. JIANG JG, Xu Y, Wu Z, Ni H, et al
    Acute myeloid leukemia developed in Ph- cells with MLL gene amplification in a patient with chronic myelogenous leukemia.
    Leuk Lymphoma. 2018 Feb 23:1-3. doi: 10.1080/10428194.2018.1436174.
    PubMed     Text format    


  240. DE LUCA G, Trasarti S, Bizzoni L, Del Giudice I, et al
    Lymphomatoid granulomatosis and large granular lymphocyte leukemia, a rare association of two lymphoproliferative disorders.
    Leuk Lymphoma. 2018 Feb 23:1-4. doi: 10.1080/10428194.2018.1439583.
    PubMed     Text format    


  241. CASEY N, Fujiwara H, Azuma T, Murakami Y, et al
    An unusual, CD4 and CD8 dual-positive, CD25 negative, tumor cell phenotype in a patient with adult T-cell leukemia/lymphoma.
    Leuk Lymphoma. 2018 Feb 21:1-3. doi: 10.1080/10428194.2018.1439168.
    PubMed     Text format    


  242. MOLICA S, Levato L, Mirabelli R, Tedeschi A, et al
    Feasibility and safety of therapy with ibrutinib after antiviral control of hepatitis B virus (HBV) reactivation in chronic lymphocytic leukemia patients.
    Leuk Lymphoma. 2018 Feb 21:1-3. doi: 10.1080/10428194.2018.1436175.
    PubMed     Text format    


  243. ROZOVSKI U, Harris DM, Li P, Liu Z, et al
    Ibrutinib inhibits free fatty acid metabolism in chronic lymphocytic leukemia.
    Leuk Lymphoma. 2018 Feb 21:1-6. doi: 10.1080/10428194.2018.1439167.
    PubMed     Text format     Abstract available


  244. VAN DE LOUW A, Desai RJ, Zhu J, Claxton DF, et al
    Characteristics of early acute respiratory distress syndrome in newly diagnosed acute myeloid leukemia.
    Leuk Lymphoma. 2018 Feb 12:1-8. doi: 10.1080/10428194.2018.1435874.
    PubMed     Text format     Abstract available


  245. IKAWA Y, Nishimura R, Maeba H, Fujiki T, et al
    Deep spontaneous molecular remission in a patient with congenital acute myeloid leukemia expressing a novel MOZ-p300 fusion transcript.
    Leuk Lymphoma. 2018 Feb 12:1-3. doi: 10.1080/10428194.2018.1434885.
    PubMed     Text format    


  246. KARANTANOU C, Godavarthy PS, Krause DS
    Targeting the bone marrow microenvironment in acute leukemia.
    Leuk Lymphoma. 2018 Feb 12:1-11. doi: 10.1080/10428194.2018.1434886.
    PubMed     Text format     Abstract available


  247. KRUPAR R, Schreiber C, Offermann A, Lengerke C, et al
    In silico analysis of anti-leukemia immune response and immune evasion in acute myeloid leukemia.
    Leuk Lymphoma. 2018 Feb 12:1-4. doi: 10.1080/10428194.2018.1434883.
    PubMed     Text format    


  248. SMIRNIKHINA SA, Chelysheva EY, Lavrov AV, Kochergin-Nikitsky KS, et al
    Genetic markers of stable molecular remission in chronic myeloid leukemia after targeted therapy discontinuation.
    Leuk Lymphoma. 2018 Feb 9:1-4. doi: 10.1080/10428194.2018.1434880.
    PubMed     Text format    


  249. ZAJAC-SPYCHALA O, Pawlak M, Karmelita-Katulska K, Pilarczyk J, et al
    Anti-leukemic treatment-induced neurotoxicity in long-term survivors of childhood acute lymphoblastic leukemia: impact of reduced central nervous system radiotherapy and intermediate- to high-dose methotrexate.
    Leuk Lymphoma. 2018 Feb 9:1-10. doi: 10.1080/10428194.2018.1434879.
    PubMed     Text format     Abstract available


  250. DERRIEUX C, Freynet N, Frayfer J, Delabesse E, et al
    A case of B-cell precursor acute lymphoblastic leukemia with IL3-IGH rearrangement revealed by thromboembolism and marked eosinophilia.
    Leuk Lymphoma. 2018 Feb 9:1-4. doi: 10.1080/10428194.2018.1430796.
    PubMed     Text format    


  251. ALVAREZ E, Muffly L, Li Q, Brunson A, et al
    Care at specialized cancer centers among young adults with acute lymphoblastic leukemia in California.
    Leuk Lymphoma. 2018 Feb 9:1-3. doi: 10.1080/10428194.2018.1427856.
    PubMed     Text format    


  252. HE F, Sapkota S, Parker S, Defor T, et al
    A real-world study of clofarabine and cytarabine combination therapy for patients with acute myeloid leukemia.
    Leuk Lymphoma. 2018 Feb 7:1-8. doi: 10.1080/10428194.2018.1433297.
    PubMed     Text format     Abstract available


  253. FLOWERS CR, Nabhan C, Kay NE, Mato A, et al
    Reasons for initiation of treatment and predictors of response for patients with Rai stage 0/1 chronic lymphocytic leukemia (CLL) receiving first-line therapy: an analysis of the Connect((R)) CLL cohort study.
    Leuk Lymphoma. 2018 Feb 7:1-9. doi: 10.1080/10428194.2018.1427860.
    PubMed     Text format     Abstract available


  254. TORREBADELL M, Diaz-Beya M, Kalko SG, Pratcorona M, et al
    A 4-gene expression prognostic signature might guide post-remission therapy in patients with intermediate-risk cytogenetic acute myeloid leukemia.
    Leuk Lymphoma. 2018 Feb 2:1-11. doi: 10.1080/10428194.2017.1422859.
    PubMed     Text format     Abstract available


  255. IMBERT V, Nebout M, Mary D, Endou H, et al
    Co-targeting intracellular pH and essential amino acid uptake cooperates to induce cell death of T-ALL/LL cells.
    Leuk Lymphoma. 2018;59:460-468.
    PubMed     Text format     Abstract available


  256. THORP BC, Badoux X
    Atrial fibrillation as a complication of ibrutinib therapy: clinical features and challenges of management.
    Leuk Lymphoma. 2018;59:311-320.
    PubMed     Text format     Abstract available


  257. BEZERRA ED, Smith H, Estey E
    A case of indolent AML with five-year survival without treatment.
    Leuk Lymphoma. 2018;59:519.
    PubMed     Text format    


  258. KASHOFER K, Gornicec M, Lind K, Caraffini V, et al
    Detection of prognostically relevant mutations and translocations in myeloid sarcoma by next generation sequencing.
    Leuk Lymphoma. 2018;59:501-504.
    PubMed     Text format    


  259. DANIELZIK T, Koldehoff M, Buttkereit U, Beelen DW, et al
    Sensitive detection of rare antigen-specific T cells directed against Wilms' tumor 1 by FluoroSpot assay.
    Leuk Lymphoma. 2018;59:490-492.
    PubMed     Text format    


  260. LAD D, Hoeppli R, Huang Q, Garcia R, et al
    Regulatory T-cells drive immune dysfunction in CLL.
    Leuk Lymphoma. 2018;59:486-489.
    PubMed     Text format    


    January 2018
  261. SCIUME M, Fracchiolla NS, Cortelezzi A
    Severe hypofibrinogenemia associated with imatinib and prednisone therapy in Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Leuk Lymphoma. 2018 Jan 31:1-2. doi: 10.1080/10428194.2018.1429603.
    PubMed     Text format    


  262. ZHANG Y, Qu S, Wang Q, Li J, et al
    A novel fusion of PDGFRB to TSC1, an intrinsic suppressor of mTOR-signaling pathway, in a chronic eosinophilic leukemia patient with t(5;9)(q32;q34).
    Leuk Lymphoma. 2018 Jan 31:1-3. doi: 10.1080/10428194.2018.1427855.
    PubMed     Text format    


  263. ANDO T, Kojima K, Sano H, Kidoguchi K, et al
    Successful treatment of post-transplant relapsed adult T cell leukemia after cord blood transplantation with low-dose, short-term lenalidomide.
    Leuk Lymphoma. 2018 Jan 31:1-4. doi: 10.1080/10428194.2018.1427859.
    PubMed     Text format    


  264. RICARD L, Abisror N, Droin N, Selimoglu-Buet D, et al
    Retroperitoneal fibrosis as extramedullary hematopoiesis of a chronic myelomonocytic leukemia.
    Leuk Lymphoma. 2018 Jan 25:1-3. doi: 10.1080/10428194.2018.1427857.
    PubMed     Text format    


  265. PANDEY G, Bakhshi S, Thakur B, Jain P, et al
    Prognostic significance of cathepsin L expression in pediatric acute myeloid leukemia.
    Leuk Lymphoma. 2018 Jan 18:1-13. doi: 10.1080/10428194.2017.1422865.
    PubMed     Text format     Abstract available


  266. GUILLEM V, Calabuig M, Brunet S, Esteve J, et al
    Bone marrow VEGFC expression is associated with multilineage dysplasia and several prognostic markers in adult acute myeloid leukemia, but not with survival.
    Leuk Lymphoma. 2018 Jan 18:1-11. doi: 10.1080/10428194.2017.1422858.
    PubMed     Text format     Abstract available


  267. LENNMYR EB, Kozlowski P, Ahlberg L, Bernell P, et al
    Real-world data on first relapse of acute lymphoblastic leukemia in patients >55 years.
    Leuk Lymphoma. 2018 Jan 18:1-4. doi: 10.1080/10428194.2017.1416369.
    PubMed     Text format    


  268. CAO L, Koh LP, Linn YC
    Successful treatment of refractory autoimmune hemolytic anemia after allogeneic hematopoietic stem cell transplantation with bortezomib.
    Leuk Lymphoma. 2018 Jan 18:1-3. doi: 10.1080/10428194.2017.1421759.
    PubMed     Text format    


  269. BODDU P, Kantarjian H, Ravandi F, Garcia-Manero G, et al
    Outcomes with lower intensity therapy in TP53-mutated acute myeloid leukemia.
    Leuk Lymphoma. 2018 Jan 17:1-4. doi: 10.1080/10428194.2017.1422864.
    PubMed     Text format    


  270. CUI J, Zhu Z, Liu S, Li Q, et al
    Monitoring of leukemia stem cells in chronic myeloid leukemia patients.
    Leuk Lymphoma. 2018 Jan 16:1-3. doi: 10.1080/10428194.2017.1421755.
    PubMed     Text format    


  271. YANG M, Xing S, Ou HL, Zhang L, et al
    Vibsanol A induces differentiation of acute myeloid leukemia cells via activation of the PKC signaling pathway and induction of ROS.
    Leuk Lymphoma. 2018 Jan 16:1-9. doi: 10.1080/10428194.2017.1421754.
    PubMed     Text format     Abstract available


  272. BLUME R, Rempel E, Manta L, Saeed BR, et al
    The molecular signature of AML with increased ALDH activity suggests a stem cell origin.
    Leuk Lymphoma. 2018 Jan 16:1-10. doi: 10.1080/10428194.2017.1422862.
    PubMed     Text format     Abstract available


  273. ZHOU H, Xu RZ, Gu Y, Shi PF, et al
    Targeting of phospho-eIF4E by homoharringtonine eradicates a distinct subset of human acute myeloid leukemia.
    Leuk Lymphoma. 2018 Jan 15:1-13. doi: 10.1080/10428194.2017.1390229.
    PubMed     Text format     Abstract available


  274. SHAO H, Zeng Z, Cen J, Zhang J, et al
    The impact of early molecular response in children and adolescents with chronic myeloid leukemia treated with imatinib: a single-center study from China.
    Leuk Lymphoma. 2018 Jan 15:1-7. doi: 10.1080/10428194.2017.1422860.
    PubMed     Text format     Abstract available


  275. COSIMATO V, Scalia G, Raia M, Gentile L, et al
    Surface endoglin (CD105) expression on acute leukemia blast cells: an extensive flow cytometry study of 1002 patients.
    Leuk Lymphoma. 2018 Jan 15:1-4. doi: 10.1080/10428194.2017.1416366.
    PubMed     Text format    


  276. HANNON M, Wilde L, Nwaoduah N, Kasner M, et al
    Chronic myelomonocytic leukemia with central nervous system involvement.
    Leuk Lymphoma. 2018 Jan 11:1-2. doi: 10.1080/10428194.2017.1422866.
    PubMed     Text format    


  277. CRAMER P, Fraser G, Santucci-Silva R, Grosicki S, et al
    Improvement of fatigue, physical functioning, and well-being among patients with severe impairment at baseline receiving ibrutinib in combination with bendamustine and rituximab for relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma in t
    Leuk Lymphoma. 2018 Jan 3:1-10. doi: 10.1080/10428194.2017.1416364.
    PubMed     Text format     Abstract available


  278. RUAN J, Gao S, Yang J, Li H, et al
    WT1 protein is cleaved by caspase-3 in apoptotic leukemic cells.
    Leuk Lymphoma. 2018;59:162-170.
    PubMed     Text format     Abstract available


  279. GUO BB, Liang J, Allcock RJN, Mirzai B, et al
    A mutation in PTPN11 may drive leukemic transformation in a case of essential thrombocythemia.
    Leuk Lymphoma. 2018;59:245-248.
    PubMed     Text format    


  280. JANAKIRAM M, Verma A, Wang Y, Budhathoki A, et al
    Accelerated leukemic transformation after haplo-identical transplantation for hydroxyurea-treated sickle cell disease.
    Leuk Lymphoma. 2018;59:241-244.
    PubMed     Text format    


  281. ZHANG Y, Cheng Z, Yan WZ, Liu SF, et al
    Molecular characterization and therapeutic reaction to dasatinib in a CML patient harboring a novel e8a2 BCR-ABL1 transcript with a somatic mutation in TP53BP2 and cadherin-10 genes.
    Leuk Lymphoma. 2018;59:233-236.
    PubMed     Text format    


    December 2017
  282. HANIF A, Wang ES, Thompson JE, Baron JI, et al
    Combining blinatumomab with targeted therapy for BCR-ABL mutant relapsed/refractory acute lymphoblastic leukemia.
    Leuk Lymphoma. 2017 Dec 18:1-3. doi: 10.1080/10428194.2017.1411595.
    PubMed     Text format    


  283. YABUSHITA T, Satake H, Maruoka H, Morita M, et al
    Expression of multiple leukemic stem cell markers is associated with poor prognosis in de novo acute myeloid leukemia.
    Leuk Lymphoma. 2017 Dec 18:1-8. doi: 10.1080/10428194.2017.1410888.
    PubMed     Text format     Abstract available


  284. GAY ND, Kozin E, Okada C, Danilov AV, et al
    Obinutuzumab monotherapy in previously untreated chronic lymphocytic leukemia.
    Leuk Lymphoma. 2017 Dec 18:1-3. doi: 10.1080/10428194.2017.1410890.
    PubMed     Text format    


  285. HALDER A, Nayak KB, Chakraborty S
    Ecotopic viral integration site 1 (EVI1) transcriptionally targets talin1 (TLN1) and upregulates its expression in chronic myeloid leukemia.
    Leuk Lymphoma. 2017 Dec 7:1-3. doi: 10.1080/10428194.2017.1406089.
    PubMed     Text format    


  286. LI H, Zhang W, Kuang P, Ye Y, et al
    Combination of IKZF1 deletion and early molecular response show significant roles on prognostic stratification in Philadelphia chromosome-positive acute lymphoblastic leukemia patients.
    Leuk Lymphoma. 2017 Dec 7:1-9. doi: 10.1080/10428194.2017.1406933.
    PubMed     Text format     Abstract available


  287. HERNANDEZ-GONZALEZ O, Ortiz-Zamudio JJ, Rodriguez-Pinal CJ, Alvarado-Morales I, et al
    Genetic polymorphisms of arylamine N-acetyltransferases 1 and 2 and the likelihood of developing pediatric acute lymphoblastic leukemia.
    Leuk Lymphoma. 2017 Dec 7:1-8. doi: 10.1080/10428194.2017.1406090.
    PubMed     Text format     Abstract available


  288. LEI H, Wang W, Wu Y
    Targeting oncoproteins for degradation by small molecules in myeloid leukemia.
    Leuk Lymphoma. 2017 Dec 4:1-8. doi: 10.1080/10428194.2017.1403600.
    PubMed     Text format     Abstract available


  289. GUPTA SK, Bakhshi S, Chopra A, Kamal VK, et al
    Molecular genetic profile in BCR-ABL1 negative pediatric B-cell acute lymphoblastic leukemia can further refine outcome prediction in addition to that by end-induction minimal residual disease detection.
    Leuk Lymphoma. 2017 Dec 3:1-6. doi: 10.1080/10428194.2017.1408087.
    PubMed     Text format     Abstract available


  290. CHENG WY, Zhu YM, Cheng S, Chen YS, et al
    Development of B-cell prolymphocytic leukemia in a patient with splenic diffuse red pulp small B-cell lymphoma.
    Leuk Lymphoma. 2017 Dec 3:1-4. doi: 10.1080/10428194.2017.1405397.
    PubMed     Text format    



  291. XVII International Workshop on Chronic Lymphocytic Leukemia 2017 May 12--15, 2017, New York.
    Leuk Lymphoma. 2017;58.
    PubMed     Text format    


    November 2017
  292. RUGGIU M, Oberkampf F, Ghez D, Cony-Makhoul P, et al
    Azacytidine in combination with tyrosine kinase inhibitors induced durable responses in patients with advanced phase chronic myelogenous leukemia.
    Leuk Lymphoma. 2017 Nov 28:1-7. doi: 10.1080/10428194.2017.1397666.
    PubMed     Text format     Abstract available


  293. RIBERA JM, Morgades M, Montesinos P, Martino R, et al
    Efficacy and safety of native versus pegylated Escherichia coli asparaginase for treatment of adults with high-risk, Philadelphia chromosome-negative acute lymphoblastic leukemia.
    Leuk Lymphoma. 2017 Nov 22:1-10. doi: 10.1080/10428194.2017.1397661.
    PubMed     Text format     Abstract available


  294. KANNA R, Choudhary G, Ramachandra N, Steidl U, et al
    STAT3 inhibition as a therapeutic strategy for leukemia.
    Leuk Lymphoma. 2017 Nov 22:1-7. doi: 10.1080/10428194.2017.1397668.
    PubMed     Text format     Abstract available


  295. PEI R, Si T, Lu Y, Zhou JX, et al
    Salvianolic acid A, a novel PI3K/Akt inhibitor, induces cell apoptosis and suppresses tumor growth in acute myeloid leukemia.
    Leuk Lymphoma. 2017 Nov 22:1-9. doi: 10.1080/10428194.2017.1399314.
    PubMed     Text format     Abstract available


  296. GOHIL SH, Maciocia N, Patrick P, Roberts T, et al
    LenD: a study to establish the safety and efficacy of lenalidomide and dexamethasone in patients with relapsed or refractory chronic lymphocytic leukemia.
    Leuk Lymphoma. 2017 Nov 22:1-4. doi: 10.1080/10428194.2017.1399311.
    PubMed     Text format    


  297. PATNAIK MM
    The importance of FLT3 mutational analysis in acute myeloid leukemia.
    Leuk Lymphoma. 2017 Nov 22:1-14. doi: 10.1080/10428194.2017.1399312.
    PubMed     Text format     Abstract available


  298. SASAKI K, Mori Y, Yoshimoto G, Sakoda T, et al
    Successful treatment of Ph ALL with hematopoietic stem cell transplantation from the same HLA-haploidentical related donor of previous liver transplantation.
    Leuk Lymphoma. 2017 Nov 22:1-3. doi: 10.1080/10428194.2017.1403021.
    PubMed     Text format    


  299. AYED AO, Parikh SA
    Management of patients with chronic lymphocytic leukemia at high risk of relapse on ibrutinib therapy.
    Leuk Lymphoma. 2017 Nov 8:1-10. doi: 10.1080/10428194.2017.1397665.
    PubMed     Text format     Abstract available


  300. MARTINEZ-TRILLOS A, Pinyol M, Delgado J, Aymerich M, et al
    The mutational landscape of small lymphocytic lymphoma compared to non-early stage chronic lymphocytic leukemia.
    Leuk Lymphoma. 2017 Nov 8:1-9. doi: 10.1080/10428194.2017.1397660.
    PubMed     Text format     Abstract available


  301. MCCURDY SR, Levis MJ
    Emerging molecular predictive and prognostic factors in acute myeloid leukemia.
    Leuk Lymphoma. 2017 Nov 2:1-19. doi: 10.1080/10428194.2017.1393669.
    PubMed     Text format     Abstract available


    October 2017
  302. SATO R, Jacob J, Gaballa S
    Rapid flare of immune thrombocytopenia after stopping ibrutinib in a patient with chronic lymphocytic leukemia.
    Leuk Lymphoma. 2017 Oct 30:1-4. doi: 10.1080/10428194.2017.1387907.
    PubMed     Text format    


  303. STEINBRECHER D, Jebaraj BMC, Schneider C, Edelmann J, et al
    Telomere length in poor-risk chronic lymphocytic leukemia: associations with disease characteristics and outcome.
    Leuk Lymphoma. 2017 Oct 24:1. doi: 10.1080/10428194.2017.1390236.
    PubMed     Text format     Abstract available


  304. YU J, Antic Z, van Reijmersdal SV, Hoischen A, et al
    Accurate detection of low-level mosaic mutations in pediatric acute lymphoblastic leukemia using single molecule tagging and deep-sequencing.
    Leuk Lymphoma. 2017 Oct 23:1-10. doi: 10.1080/10428194.2017.1390232.
    PubMed     Text format     Abstract available


  305. SALZER W, Bostrom B, Messinger Y, Perissinotti AJ, et al
    Asparaginase activity levels and monitoring in patients with acute lymphoblastic leukemia.
    Leuk Lymphoma. 2017 Oct 18:1-10. doi: 10.1080/10428194.2017.1386305.
    PubMed     Text format     Abstract available


  306. PENG L, Tang Y, Zhang Y, Guo S, et al
    Structural maintenance of chromosomes 4 is required for leukemia stem cell maintenance in MLL-AF9 induced acute myeloid leukemia.
    Leuk Lymphoma. 2017 Oct 18:1-8. doi: 10.1080/10428194.2017.1387906.
    PubMed     Text format     Abstract available


  307. GEYER MB, Manjunath SH, Evans AG, Park JH, et al
    Concurrent therapy of chronic lymphocytic leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia utilizing CD19-targeted CAR T-cells.
    Leuk Lymphoma. 2017 Oct 18:1-5. doi: 10.1080/10428194.2017.1390237.
    PubMed     Text format    


  308. LI WY, Wang Y, Chen SN, Qiu HY, et al
    Consolidation therapy with decitabine and intermediate-dose cytarabine followed by HLA-mismatched peripheral blood stem cells infusion for older patients with acute myeloid leukemia in first remission.
    Leuk Lymphoma. 2017 Oct 18:1-7. doi: 10.1080/10428194.2017.1390235.
    PubMed     Text format     Abstract available


  309. MITSUI-SEKINAKA K, Sekinaka Y, Ogura Y, Honda M, et al
    A pediatric case of acute megakaryocytic leukemia with double chimeric transcripts of CBFA2T3-GLIS2 and DHH-RHEBL1.
    Leuk Lymphoma. 2017 Oct 18:1-3. doi: 10.1080/10428194.2017.1387901.
    PubMed     Text format    


  310. CORROCHER FA, Bueno de Paiva L, Duarte ASS, Ferro KP, et al
    Reduced expression of NR4A1 activates glycolytic pathway in acute promyelocytic leukemia cells.
    Leuk Lymphoma. 2017 Oct 17:1-4. doi: 10.1080/10428194.2017.1387900.
    PubMed     Text format    


  311. MOTOHASHI K, Fujisawa S, Doki N, Kobayashi T, et al
    Cytogenetic risk stratification may predict allogeneic hematopoietic stem cell transplantation outcomes for chronic myelomonocytic leukemia.
    Leuk Lymphoma. 2017 Oct 16:1-6. doi: 10.1080/10428194.2017.1387913.
    PubMed     Text format     Abstract available


  312. LEE LJ, Toze CL, Huang SJT, Gillan TL, et al
    Improved survival outcomes with the addition of rituximab to initial therapy for chronic lymphocytic leukemia: a comparative effectiveness analysis in the province of British Columbia, Canada.
    Leuk Lymphoma. 2017 Oct 16:1-8. doi: 10.1080/10428194.2017.1387904.
    PubMed     Text format     Abstract available


  313. ZHANG C, Amos Burke GA
    Pediatric precursor B-cell acute lymphoblastic leukemia with MYC 8q24 translocation - how to treat?
    Leuk Lymphoma. 2017 Oct 12:1-7. doi: 10.1080/10428194.2017.1387914.
    PubMed     Text format     Abstract available


  314. KATAGIRI S, Umezu T, Azuma K, Asano M, et al
    Hidden FLT3-D835Y clone in FLT3-ITD-positive acute myeloid leukemia that evolved into very late relapse with T-lymphoblastic leukemia.
    Leuk Lymphoma. 2017 Oct 3:1-4. doi: 10.1080/10428194.2017.1382696.
    PubMed     Text format    


  315. VANGAPANDU HV, Chen H, Wierda WG, Keating MJ, et al
    Proteomics profiling identifies induction of caveolin-1 in chronic lymphocytic leukemia cells by bone marrow stromal cells.
    Leuk Lymphoma. 2017 Oct 3:1-12. doi: 10.1080/10428194.2017.1376747.
    PubMed     Text format     Abstract available


    September 2017
  316. HOOGEVEEN PG, de Bie M, Noordijk R, Sonneveld E, et al
    Pitfalls in short-tandem repeat analysis as quality control for sample mix-up of pediatric acute lymphoblastic leukemia patients.
    Leuk Lymphoma. 2017 Sep 28:1-3. doi: 10.1080/10428194.2017.1382699.
    PubMed     Text format    


  317. APPLEBY N, O'Brien D, Quinn FM, Smyth L, et al
    Risk adjusted therapy in chronic lymphocytic leukemia: a phase II cancer trials Ireland (CTRIAL-IE [ICORG 07-01]) study of fludarabine, cyclophosphamide, and rituximab therapy evaluating response adapted, abbreviated frontline therapy with FCR in non-
    Leuk Lymphoma. 2017 Sep 19:1-10. doi: 10.1080/10428194.2017.1376746.
    PubMed     Text format     Abstract available


  318. ANDRITSOS LA, Grieselhuber NR, Anghelina M, Rogers KA, et al
    Trametinib for the treatment of IGHV4-34, MAP2K1-mutant variant hairy cell leukemia.
    Leuk Lymphoma. 2017 Sep 18:1-4. doi: 10.1080/10428194.2017.1365853.
    PubMed     Text format    


  319. KREINITZ N, Polliack A, Tadmor T
    Chronic lymphocytic leukemia is becoming more complex: how to define complex karyotype?
    Leuk Lymphoma. 2017 Sep 18:1-2. doi: 10.1080/10428194.2017.1376748.
    PubMed     Text format    


  320. RIZZOTTO L, Lai TH, Bottoni A, Woyach JA, et al
    Role and regulation of microRNAs targeting BTK in acute myelogenous leukemia.
    Leuk Lymphoma. 2017 Sep 18:1-5. doi: 10.1080/10428194.2017.1376742.
    PubMed     Text format    


  321. VLIJM-KIEVIT A, Jorna NGE, Moll E, Pajkrt E, et al
    Acute lymphoblastic leukemia during the third trimester of pregnancy.
    Leuk Lymphoma. 2017 Sep 15:1-3. doi: 10.1080/10428194.2017.1375104.
    PubMed     Text format    


  322. MULANOVICH V, Kontoyiannis DP
    Acute myeloid leukemia and the infectious diseases consultant.
    Leuk Lymphoma. 2017 Sep 15:1-8. doi: 10.1080/10428194.2017.1365861.
    PubMed     Text format     Abstract available


  323. MESCHER C, Gilbertson D, Randall NM, Tarchand G, et al
    The impact of Agent Orange exposure on prognosis and management in patients with chronic lymphocytic leukemia: a National Veteran Affairs Tumor Registry Study.
    Leuk Lymphoma. 2017 Sep 14:1-8. doi: 10.1080/10428194.2017.1375109.
    PubMed     Text format     Abstract available


  324. VAUGHN JL, Kline D, Denlinger NM, Andritsos LA, et al
    Predictive performance of early warning scores in acute leukemia patients receiving induction chemotherapy.
    Leuk Lymphoma. 2017 Sep 13:1-3. doi: 10.1080/10428194.2017.1376744.
    PubMed     Text format    


  325. TAVARES M, Lemiale V, Mokart D, Pene F, et al
    Determinants of 1-year survival in critically ill acute leukemia patients: a GRRR-OH study.
    Leuk Lymphoma. 2017 Sep 13:1-9. doi: 10.1080/10428194.2017.1375106.
    PubMed     Text format     Abstract available


  326. PULA A, Stawiski K, Braun M, Iskierka-Jazdzewska E, et al
    Efficacy and safety of B-cell receptor signaling pathway inhibitors in relapsed/refractory chronic lymphocytic leukemia: a systematic review and meta-analysis of randomized clinical trials.
    Leuk Lymphoma. 2017 Sep 11:1-11. doi: 10.1080/10428194.2017.1375101.
    PubMed     Text format     Abstract available


  327. PALLAVAJJALA A, Kim D, Li T, Ghiaur G, et al
    Genomic characterization of chromosome translocations in patients with T/myeloid mixed-phenotype acute leukemia.
    Leuk Lymphoma. 2017 Sep 7:1-8. doi: 10.1080/10428194.2017.1372577.
    PubMed     Text format     Abstract available


  328. SHUKLA A, Shukla V, Joshi SS
    Regulation of MAPK signaling and implications in chronic lymphocytic leukemia.
    Leuk Lymphoma. 2017 Sep 7:1-9. doi: 10.1080/10428194.2017.1370548.
    PubMed     Text format     Abstract available


  329. RODRIGUEZ CM, Stanganelli C, Bussi C, Arroyo D, et al
    Intracytoplasmic filamentous inclusions and IGHV rearrangements in a patient with chronic lymphocytic leukemia.
    Leuk Lymphoma. 2017 Sep 3:1-5. doi: 10.1080/10428194.2017.1370549.
    PubMed     Text format    


  330. GURBUXANI S
    The web of microRNA in B lymphoblastic leukemia.
    Leuk Lymphoma. 2017;58:2024-2025.
    PubMed     Text format    


    August 2017
  331. HUANG A, Huang C, Tang G, Cheng H, et al
    Impact of clinical utility of MRD assessment with different techniques on survival in acute B lymphoblastic leukemia.
    Leuk Lymphoma. 2017 Aug 31:1-11. doi: 10.1080/10428194.2017.1369072.
    PubMed     Text format     Abstract available


  332. BURGSTALLER S, Stauder R, Kuehr T, Lang A, et al
    A phase I study of lenalidomide in patients with chronic myelomonocytic leukemia (CMML) - AGMT_CMML-1.
    Leuk Lymphoma. 2017 Aug 30:1-6. doi: 10.1080/10428194.2017.1369070.
    PubMed     Text format     Abstract available


  333. CAO H, Xie J, Guo L, Han K, et al
    All-trans retinoic acid induces autophagic degradation of ubiquitin-like modifier activating enzyme 3 in acute promyelocytic leukemia cells.
    Leuk Lymphoma. 2017 Aug 29:1-9. doi: 10.1080/10428194.2017.1365850.
    PubMed     Text format     Abstract available


  334. BODDU P, Kantarjian H, Garcia-Manero G, Ravandi F, et al
    Time to response and survival in hypomethylating agent-treated acute myeloid leukemia.
    Leuk Lymphoma. 2017 Aug 25:1-4. doi: 10.1080/10428194.2017.1365857.
    PubMed     Text format    


  335. FALANTES J, Pleyer L, Thepot S, Almeida AM, et al
    Real life experience with frontline azacitidine in a large series of older adults with acute myeloid leukemia stratified by MRC/LRF score: results from the expanded international E-ALMA series (E-ALMA+).
    Leuk Lymphoma. 2017 Aug 24:1-8. doi: 10.1080/10428194.2017.1365854.
    PubMed     Text format     Abstract available


  336. IACCARINO L, Ottone T, Hasan SK, Divona M, et al
    Comparative genomic analysis of PML and RARA breakpoints in paired diagnosis/relapse samples of patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy.
    Leuk Lymphoma. 2017 Aug 24:1-3. doi: 10.1080/10428194.2017.1369067.
    PubMed     Text format    


  337. SI T, Lu Y, Li F, Jiang L, et al
    High expression of INHBA is an adverse prognostic factor for de novo acute myeloid leukemia.
    Leuk Lymphoma. 2017 Aug 24:1-7. doi: 10.1080/10428194.2017.1324157.
    PubMed     Text format     Abstract available



  338. Wendtner C-M, and Gregor M. Current perspectives on the role of chemotherapy in chronic lymphocytic leukemia. Leuk Lymphoma. 2017. http://dx.doi.org/10.1080/10428194.2017.1330474.
    Leuk Lymphoma. 2017 Aug 10:1. doi: 10.1080/10428194.2017.1363546.
    PubMed     Text format    


  339. CRUZ NM, Sugita M, Ewing-Crystal N, Lam L, et al
    Selection and characterization of antibody clones are critical for accurate flow cytometry-based monitoring of CD123 in acute myeloid leukemia.
    Leuk Lymphoma. 2017 Aug 10:1-5. doi: 10.1080/10428194.2017.1361023.
    PubMed     Text format    


  340. JALBUT MM, Brunner AM, Amrein PC, Ballen KK, et al
    Early infectious complications among patients treated with induction compared to hypomethylating therapy for acute myeloid leukemia.
    Leuk Lymphoma. 2017 Aug 9:1-4. doi: 10.1080/10428194.2017.1361028.
    PubMed     Text format    


  341. CHEN X, Dou H, Wang X, Huang Y, et al
    KIT mutations correlate with adverse survival in children with core-binding factor acute myeloid leukemia.
    Leuk Lymphoma. 2017 Aug 9:1-8. doi: 10.1080/10428194.2017.1361025.
    PubMed     Text format     Abstract available


  342. CAYSSIALS E, Tartarin F, Guilhot J, Sorel N, et al
    Sustained molecular response in chronic myeloid leukemia deep responders treated with low dose tyrosine kinase inhibitors.
    Leuk Lymphoma. 2017 Aug 9:1-4. doi: 10.1080/10428194.2017.1357178.
    PubMed     Text format    


  343. DHERE V, Edelman S, Waller EK, Langston A, et al
    Myeloablative busulfan/cytoxan conditioning versus reduced-intensity fludarabine/melphalan conditioning for allogeneic hematopoietic stem cell transplant in patients with acute myelogenous leukemia.
    Leuk Lymphoma. 2017 Aug 7:1-7. doi: 10.1080/10428194.2017.1361027.
    PubMed     Text format     Abstract available


  344. KIVIOJA JL, Lopez Marti JM, Kumar A, Kontro M, et al
    Chimeric NUP98-NSD1 transcripts from the cryptic t(5;11)(q35.2;p15.4) in adult de novo acute myeloid leukemia.
    Leuk Lymphoma. 2017 Aug 4:1-8. doi: 10.1080/10428194.2017.1357174.
    PubMed     Text format     Abstract available


  345. DIRSE V, Norvilas R, Gineikiene E, Matuzeviciene R, et al
    ETV6 and NOTCH1 germline variants in adult acute leukemia.
    Leuk Lymphoma. 2017 Aug 4:1-3. doi: 10.1080/10428194.2017.1359742.
    PubMed     Text format    


  346. SESE L, Rivaud E, Bron C, Leblond V, et al
    Unexpected Pneumocystis jirovecii pneumonia in patients with untreated chronic lymphocytic leukemia.
    Leuk Lymphoma. 2017 Aug 3:1-4. doi: 10.1080/10428194.2017.1357170.
    PubMed     Text format    


  347. MULCAHY A, Mulligan SP, Shumack SP
    Recommendations for skin cancer monitoring for patients with chronic lymphocytic leukemia.
    Leuk Lymphoma. 2017 Aug 3:1-5. doi: 10.1080/10428194.2017.1349903.
    PubMed     Text format    


  348. WANG A, Cai X, Qiang P, Duan Q, et al
    Successful treatment of a patient with acute promyelocytic leukemia with a STAT5B/RARA fusion gene using decitabine.
    Leuk Lymphoma. 2017 Aug 1:1-3. doi: 10.1080/10428194.2017.1357176.
    PubMed     Text format    


    July 2017
  349. YANADA M, Mori J, Aoki J, Harada K, et al
    Effect of cytogenetic risk status on outcomes for patients with acute myeloid leukemia undergoing various types of allogeneic hematopoietic cell transplantation: an analysis of 7812 patients.
    Leuk Lymphoma. 2017 Jul 28:1-9. doi: 10.1080/10428194.2017.1357173.
    PubMed     Text format     Abstract available


  350. GEYER MB, Tallman MS
    Digging deeper in relapsed acute lymphoblastic leukemia: impact of MRD status on outcome in second remission.
    Leuk Lymphoma. 2017 Jul 28:1-3. doi: 10.1080/10428194.2017.1355971.
    PubMed     Text format    


  351. KONG J, Zhao XS, Qin YZ, Zhu HH, et al
    The initial level of MLL-partial tandem duplication affects the clinical outcomes in patients with acute myeloid leukemia.
    Leuk Lymphoma. 2017 Jul 26:1-6. doi: 10.1080/10428194.2017.1352091.
    PubMed     Text format     Abstract available


  352. ALDOSS I, Stein AS
    Advances in adult acute lymphoblastic leukemia therapy.
    Leuk Lymphoma. 2017 Jul 26:1-18. doi: 10.1080/10428194.2017.1354372.
    PubMed     Text format     Abstract available


  353. STRICKLER N, Balabanov S, Casauro K, Schanz U, et al
    Acute central nervous system complications and ammonium levels in adult patients with acute lymphoblastic leukemia receiving l-asparaginase.
    Leuk Lymphoma. 2017 Jul 21:1-8. doi: 10.1080/10428194.2017.1352090.
    PubMed     Text format     Abstract available


  354. GONZALEZ-GASCON Y MARIN I, Hernandez-Sanchez M, Rodriguez-Vicente AE, Puiggros A, et al
    Characterizing patients with multiple chromosomal aberrations detected by FISH in chronic lymphocytic leukemia.
    Leuk Lymphoma. 2017 Jul 21:1-10. doi: 10.1080/10428194.2017.1349901.
    PubMed     Text format     Abstract available


  355. ENGLAND JT, Leitch HA
    Chronic lymphocytic leukemia in a patient with well-controlled HIV infection: successful treatment with ibrutinib.
    Leuk Lymphoma. 2017 Jul 21:1-3. doi: 10.1080/10428194.2017.1349904.
    PubMed     Text format    


  356. SHLIAKHTSITSAVA K, Romero SAD, Dewald SR, Su HI, et al
    Pregnancy and child health outcomes in pediatric and young adult leukemia and lymphoma survivors: a systematic review.
    Leuk Lymphoma. 2017 Jul 21:1-17. doi: 10.1080/10428194.2017.1352097.
    PubMed     Text format     Abstract available


  357. ALLAN JN, Roboz GJ, Askin G, Ritchie E, et al
    CD25 expression and outcomes in older patients with acute myelogenous leukemia treated with plerixafor and decitabine.
    Leuk Lymphoma. 2017 Jul 18:1-8. doi: 10.1080/10428194.2017.1352089.
    PubMed     Text format     Abstract available


  358. SHORT NJ, Kantarjian H, Ravandi F, Huang X, et al
    A phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia.
    Leuk Lymphoma. 2017 Jul 18:1-8. doi: 10.1080/10428194.2017.1349907.
    PubMed     Text format     Abstract available


  359. RAUSCH CR, Marini BL, Benitez LL, Elias A, et al
    PEGging down risk factors for peg-asparaginase hepatotoxicity in patients with acute lymphoblastic leukemia dagger.
    Leuk Lymphoma. 2017 Jul 18:1-8. doi: 10.1080/10428194.2017.1349902.
    PubMed     Text format     Abstract available


  360. AMMANN EM, Shanafelt TD, Wright KB, McDowell BD, et al
    Updating survival estimates in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) based on treatment-free interval length.
    Leuk Lymphoma. 2017 Jul 18:1-7. doi: 10.1080/10428194.2017.1349905.
    PubMed     Text format     Abstract available


  361. HOROWITZ NA, Henig I, Henig O, Benyamini N, et al
    Acute myeloid leukemia during pregnancy: a systematic review and meta-analysis.
    Leuk Lymphoma. 2017 Jul 13:1-7. doi: 10.1080/10428194.2017.1347651.
    PubMed     Text format     Abstract available


  362. CHELYSHEVA E, Turkina A, Polushkina E, Shmakov R, et al
    Placental transfer of tyrosine kinase inhibitors used for chronic myeloid leukemia treatment.
    Leuk Lymphoma. 2017 Jul 13:1-6. doi: 10.1080/10428194.2017.1347929.
    PubMed     Text format     Abstract available


  363. WILLIAMS AM, Baran AM, Meacham PJ, Feldman MM, et al
    Analysis of the risk of infection in patients with chronic lymphocytic leukemia in the era of novel therapies.
    Leuk Lymphoma. 2017 Jul 11:1-8. doi: 10.1080/10428194.2017.1347931.
    PubMed     Text format     Abstract available


  364. KREMER B, Tsai DE, Debonera F, Cohen PL, et al
    Spontaneous remission of acute myeloid leukemia after discontinuation of lenalidomide.
    Leuk Lymphoma. 2017 Jul 11:1-3. doi: 10.1080/10428194.2017.1347652.
    PubMed     Text format    


  365. GARRISI VM, Sgherza N, Breccia M, Iacobazzi A, et al
    Association between proteomic profile and molecular response in chronic myeloid leukemia patients.
    Leuk Lymphoma. 2017 Jul 11:1-3. doi: 10.1080/10428194.2017.1344841.
    PubMed     Text format    


  366. DAMLAJ M, Al Balwi M, Al Mugairi AM
    Ibrutinib therapy is effective in B-cell prolymphocytic leukemia exhibiting MYC aberrations.
    Leuk Lymphoma. 2017 Jul 11:1-4. doi: 10.1080/10428194.2017.1347653.
    PubMed     Text format    


  367. SAYGIN C, Papadantonakis N, Cassaday RD, Liedtke M, et al
    Prognostic impact of incomplete hematologic count recovery and minimal residual disease on outcome in adult acute lymphoblastic leukemia at the time of second complete response.
    Leuk Lymphoma. 2017 Jul 11:1-9. doi: 10.1080/10428194.2017.1344842.
    PubMed     Text format     Abstract available


  368. CALVELLO C, Rocca B, Klersy C, Zappatore R, et al
    Alternative splicing of hTERT: a further mechanism for the control of active hTERT in acute myeloid leukemia.
    Leuk Lymphoma. 2017 Jul 6:1-8. doi: 10.1080/10428194.2017.1346252.
    PubMed     Text format     Abstract available


  369. SALMOIRAGHI S, Rambaldi A, Spinelli O
    TP53 in adult acute lymphoblastic leukemia.
    Leuk Lymphoma. 2017 Jul 6:1-12. doi: 10.1080/10428194.2017.1344839.
    PubMed     Text format     Abstract available


  370. XU W, Li X, Quan L, Yao J, et al
    Arsenic trioxide decreases the amount and inhibits the function of regulatory T cells, which may contribute to its efficacy in the treatment of acute promyelocytic leukemia.
    Leuk Lymphoma. 2017 Jul 6:1-10. doi: 10.1080/10428194.2017.1346253.
    PubMed     Text format     Abstract available


  371. HAMPRAS SS, Locke FL, Chavez JC, Patel NS, et al
    Prevalence of cutaneous viral infections in incident cutaneous squamous cell carcinoma detected among chronic lymphocytic leukemia and hematopoietic stem cell transplant patients.
    Leuk Lymphoma. 2017 Jul 6:1-7. doi: 10.1080/10428194.2017.1342822.
    PubMed     Text format     Abstract available


  372. XU L, Zhang M, Li H, Guan W, et al
    SH3BGRL as a novel prognostic biomarker is down-regulated in acute myeloid leukemia.
    Leuk Lymphoma. 2017 Jul 6:1-13. doi: 10.1080/10428194.2017.1344843.
    PubMed     Text format     Abstract available


    June 2017
  373. KATKISH LA, Rangaraju S, Rector TS, Gravely AA, et al
    Incidence of unprovoked venous thromboembolic events in patients with chronic lymphocytic leukemia.
    Leuk Lymphoma. 2017 Jun 27:1-3. doi: 10.1080/10428194.2017.1341979.
    PubMed     Text format    


  374. SANDOVAL-SUS JD, Chavez JC, Dalia S, Naqvi SMH, et al
    Association between immunoglobulin heavy-chain variable region mutational status and isolated favorable baseline genomic aberrations in chronic lymphocytic leukemia.
    Leuk Lymphoma. 2017 Jun 22:1-10. doi: 10.1080/10428194.2017.1323271.
    PubMed     Text format     Abstract available


  375. BORUTINSKAITE V, Virksaite A, Gudelyte G, Navakauskiene R, et al
    Green tea polyphenol EGCG causes anti-cancerous epigenetic modulations in acute promyelocytic leukemia cells.
    Leuk Lymphoma. 2017 Jun 22:1-10. doi: 10.1080/10428194.2017.1339881.
    PubMed     Text format     Abstract available


  376. MAFFEI R, Fiorcari S, Martinelli S, Benatti S, et al
    Increased SHISA3 expression characterizes chronic lymphocytic leukemia patients sensitive to lenalidomide.
    Leuk Lymphoma. 2017 Jun 22:1-11. doi: 10.1080/10428194.2017.1339872.
    PubMed     Text format     Abstract available


  377. SANIKOMMU SR, Clemente MJ, Chomczynski P, Afable MG 2nd, et al
    Clinical features and treatment outcomes in large granular lymphocytic leukemia (LGLL).
    Leuk Lymphoma. 2017 Jun 20:1-7. doi: 10.1080/10428194.2017.1339880.
    PubMed     Text format     Abstract available


  378. VILLEMAGNE SANCHEZ LA, O'Callaghan C, Gough K, Hall K, et al
    Patient perceptions of treatment-free remission in chronic myeloid leukemia.
    Leuk Lymphoma. 2017 Jun 15:1-10. doi: 10.1080/10428194.2017.1337114.
    PubMed     Text format     Abstract available


  379. KANSAGRA A, Dahiya S, Litzow M
    Continuing challenges and current issues in acute lymphoblastic leukemia.
    Leuk Lymphoma. 2017 Jun 11:1-16. doi: 10.1080/10428194.2017.1335397.
    PubMed     Text format     Abstract available


  380. FARSHCHI ZARABI S, Chan S, Gupta V, Khalaf D, et al
    Remissions after third induction chemotherapy for primary non-responders with acute myeloid leukemia (AML) are uncommon and short-lived.
    Leuk Lymphoma. 2017 Jun 9:1-4. doi: 10.1080/10428194.2017.1323273.
    PubMed     Text format    


  381. DROIN N, Lucas N, Parinet V, Selimoglu-Buet D, et al
    Eosinophil-rich tissue infiltrates in chronic myelomonocytic leukemia patients.
    Leuk Lymphoma. 2017 Jun 8:1-5. doi: 10.1080/10428194.2017.1330468.
    PubMed     Text format     Abstract available


  382. LARSEN CM, Villarraga HR, Begna KH, Litzow MR, et al
    Cardiovascular effects of the addition of nilotinib to standard therapy for acute myeloid leukemia.
    Leuk Lymphoma. 2017 Jun 8:1-4. doi: 10.1080/10428194.2017.1323268.
    PubMed     Text format    


  383. TIONG IS, Tan P, McManus J, Cummings N, et al
    Phase Ib study of the mTOR inhibitor everolimus with low dose cytarabine in elderly acute myeloid leukemia.
    Leuk Lymphoma. 2017 Jun 8:1-4. doi: 10.1080/10428194.2017.1334122.
    PubMed     Text format    


  384. NASILLO V, Paolini A, Riva G, Morselli M, et al
    Effectiveness of originator (Neupogen) and biosimilar (Zarzio) filgrastim in autologous peripheral blood stem cell mobilization in adults with acute myeloid leukemia: a single-center retrospective study.
    Leuk Lymphoma. 2017 Jun 7:1-4. doi: 10.1080/10428194.2017.1321748.
    PubMed     Text format    


  385. MEGIAS-VERICAT JE, Montesinos P, Herrero MJ, Moscardo F, et al
    Influence of cytarabine metabolic pathway polymorphisms in acute myeloid leukemia induction treatment.
    Leuk Lymphoma. 2017 Jun 2:1-15. doi: 10.1080/10428194.2017.1323267.
    PubMed     Text format     Abstract available


  386. BHATT VR, Gundabolu K, Koll T, Maness LJ, et al
    Initial therapy for acute myeloid leukemia in older patients: principles of care.
    Leuk Lymphoma. 2017 Jun 2:1-13. doi: 10.1080/10428194.2017.1323275.
    PubMed     Text format     Abstract available


  387. SOLE C, Martinez D, Gine E, Gonzalez-Farre B, et al
    Expression of a truncated B lymphocyte-induced maturation protein-1 isoform is associated with an incomplete plasmacytic differentiation program in chronic lymphocytic leukemia.
    Leuk Lymphoma. 2017 Jun 2:1-4. doi: 10.1080/10428194.2017.1330470.
    PubMed     Text format    


  388. NGUYEN D, Haley L, Pallavajjala A, Gojo I, et al
    Identification of a novel KMT2A-SEPT14 fusion in acute myeloid leukemia.
    Leuk Lymphoma. 2017 Jun 2:1-3. doi: 10.1080/10428194.2017.1324163.
    PubMed     Text format    


  389. WEBSTER JA, Pratz KW
    Acute myeloid leukemia in the elderly: therapeutic options and choice.
    Leuk Lymphoma. 2017 Jun 2:1-14. doi: 10.1080/10428194.2017.1330956.
    PubMed     Text format     Abstract available


  390. WENDTNER CM, Gregor M
    Current perspectives on the role of chemotherapy in chronic lymphocytic leukemia.
    Leuk Lymphoma. 2017 Jun 1:1-11. doi: 10.1080/10428194.2017.1330474.
    PubMed     Text format     Abstract available


  391. PIGGIN A, Bayly E, Tam CS
    Novel agents versus chemotherapy as frontline treatment of CLL.
    Leuk Lymphoma. 2017;58:1320-1324.
    PubMed     Text format     Abstract available


    May 2017
  392. GAFTER-GVILI A
    G6PD deficiency and fungal infections in patients with acute myeloid leukemia: less enzyme more fungus.
    Leuk Lymphoma. 2017 May 31:1-2. doi: 10.1080/10428194.2017.1330478.
    PubMed     Text format    


  393. MOTLLO C, Ribera JM, Morgades M, Granada I, et al
    Frequency and prognostic significance of additional cytogenetic abnormalities to the Philadelphia chromosome in young and older adults with acute lymphoblastic leukemia.
    Leuk Lymphoma. 2017 May 30:1-9. doi: 10.1080/10428194.2017.1326596.
    PubMed     Text format     Abstract available


  394. LEE SE, Choi SY, Kim SH, Song HY, et al
    Baseline BCR-ABL1 transcript type of e13a2 and large spleen size are predictors of poor long-term outcomes in chronic phase chronic myeloid leukemia patients who failed to achieve an early molecular response after 3 months of imatinib therapy.
    Leuk Lymphoma. 2017 May 25:1-9. doi: 10.1080/10428194.2017.1320711.
    PubMed     Text format     Abstract available


  395. SAINI L, Brandwein J, Szkotak A, Ghosh S, et al
    Persistent cytogenetic abnormalities in patients undergoing intensive chemotherapy for acute myeloid leukemia.
    Leuk Lymphoma. 2017 May 25:1-8. doi: 10.1080/10428194.2017.1326032.
    PubMed     Text format     Abstract available


  396. XU X, Nagel S, Quentmeier H, Wang Z, et al
    KDM3B shows tumor-suppressive activity and transcriptionally regulates HOXA1 through retinoic acid response elements in acute myeloid leukemia.
    Leuk Lymphoma. 2017 May 25:1-10. doi: 10.1080/10428194.2017.1324156.
    PubMed     Text format     Abstract available


  397. HOSHINO T, Taki T, Takada S, Hatsumi N, et al
    Spontaneous remission of adult acute myeloid leukemia with t(8;16)(p11;p13)/MOZ-CBP fusion.
    Leuk Lymphoma. 2017 May 23:1-3. doi: 10.1080/10428194.2017.1320712.
    PubMed     Text format    


  398. BRECCIA M, Efficace F
    Are chronic myeloid leukemia patients ready to stop long-term treatment?
    Leuk Lymphoma. 2017 May 23:1-3. doi: 10.1080/10428194.2017.1330476.
    PubMed     Text format    


  399. LARSON RA
    Managing CNS disease in adults with acute lymphoblastic leukemia.
    Leuk Lymphoma. 2017 May 23:1-11. doi: 10.1080/10428194.2017.1326597.
    PubMed     Text format     Abstract available


  400. BUTTNER B, Knoth H, Kramer M, Oertel R, et al
    Impact of pharmacokinetics on the toxicity and efficacy of clofarabine in patients with relapsed or refractory acute myeloid leukemia.
    Leuk Lymphoma. 2017 May 16:1-10. doi: 10.1080/10428194.2017.1319051.
    PubMed     Text format     Abstract available


  401. TANOUE S, Konuma T, Takahashi S, Watanabe E, et al
    Long-term persistent donor-recipient mixed chimerism without disease recurrence after myeloablative single-unit cord blood transplantation in adult acute myeloid leukemia following myelodysplastic syndrome.
    Leuk Lymphoma. 2017 May 16:1-3. doi: 10.1080/10428194.2017.1318440.
    PubMed     Text format    


  402. CAMPREGHER PV, Halley NDS, Vieira GA, Fernandes JF, et al
    Identification of a novel fusion TBL1XR1-PDGFRB in a patient with acute myeloid leukemia harboring the DEK-NUP214 fusion and clinical response to dasatinib.
    Leuk Lymphoma. 2017 May 16:1-4. doi: 10.1080/10428194.2017.1318437.
    PubMed     Text format    


  403. OWEN C, Christofides A, Johnson N, Lawrence T, et al
    Use of minimal residual disease assessment in the treatment of chronic lymphocytic leukemia.
    Leuk Lymphoma. 2017 May 16:1-9. doi: 10.1080/10428194.2017.1318439.
    PubMed     Text format     Abstract available


  404. BUSCA A, Lessi F, Verga L, Candoni A, et al
    SEIFEM 2010-E: economic evaluation of posaconazole for antifungal prophylaxis in patients with acute myeloid leukemia receiving induction chemotherapy.
    Leuk Lymphoma. 2017 May 16:1-6. doi: 10.1080/10428194.2017.1318438.
    PubMed     Text format     Abstract available


  405. OKABE S, Tauchi T, Tanaka Y, Ohyashiki K, et al
    Targeting peroxisome proliferator-activated receptors: a novel strategy for Philadelphia chromosome-positive leukemia cells.
    Leuk Lymphoma. 2017 May 15:1-3. doi: 10.1080/10428194.2017.1312373.
    PubMed     Text format    


  406. ZHAO B, Bhattacharya S, Yu Q, Fuchs SY, et al
    Expression of the IFNAR1 chain of type 1 interferon receptor in benign cells protects against progression of acute leukemia.
    Leuk Lymphoma. 2017 May 15:1-7. doi: 10.1080/10428194.2017.1319053.
    PubMed     Text format     Abstract available


  407. SHANMUGANATHAN N, Hiwase DK, Ross DM
    Treatment of chronic myeloid leukemia: assessing risk, monitoring response, and optimizing outcome.
    Leuk Lymphoma. 2017 May 9:1-12. doi: 10.1080/10428194.2017.1312377.
    PubMed     Text format     Abstract available


  408. AW A, Brown JR
    The potential combination of BCL-2 inhibitors and ibrutinib as frontline therapy in chronic lymphocytic leukemia.
    Leuk Lymphoma. 2017 May 9:1-11. doi: 10.1080/10428194.2017.1312387.
    PubMed     Text format     Abstract available


  409. COLOMER-LAHIGUERA S, Pisecker M, Konig M, Nebral K, et al
    MEF2C-dysregulated pediatric T-cell acute lymphoblastic leukemia is associated with CDKN1B deletions and a poor response to glucocorticoid therapy.
    Leuk Lymphoma. 2017 May 9:1-10. doi: 10.1080/10428194.2017.1312383.
    PubMed     Text format     Abstract available


    April 2017
  410. LIU H, Zhang J, Ren S, Chen M, et al
    Using low-dose homoharringtonine and cytarabine in combination with granulocyte colony-stimulating factor in a priming induction therapy for acute myeloid leukemia: a retrospective study of 29 cases in china.
    Leuk Lymphoma. 2017 Apr 13:1-4. doi: 10.1080/10428194.2017.1312378.
    PubMed     Text format    


  411. DRENNAN AC, Rui L
    HiJAKing the epigenome in leukemia and lymphoma.
    Leuk Lymphoma. 2017 Apr 12:1-8. doi: 10.1080/10428194.2017.1312370.
    PubMed     Text format     Abstract available


  412. SANNA M, Caocci G, Ledda A, Orru F, et al
    Glucose-6-phosphate dehydrogenase deficiency and risk of invasive fungal disease in patients with acute myeloid leukemia.
    Leuk Lymphoma. 2017 Apr 12:1-10. doi: 10.1080/10428194.2017.1312666.
    PubMed     Text format     Abstract available


  413. BOSCH R, Mora A, Vicente EP, Ferrer G, et al
    FcgammaRIIb expression in early stage chronic lymphocytic leukemia.
    Leuk Lymphoma. 2017 Apr 4:1-7. doi: 10.1080/10428194.2017.1307981.
    PubMed     Text format     Abstract available


  414. WASHIO K, Oka T, Abdalkader L, Muraoka M, et al
    Gene expression analysis of hypersensitivity to mosquito bite, chronic active EBV infection and NK/T-lymphoma/leukemia.
    Leuk Lymphoma. 2017 Apr 3:1-12. doi: 10.1080/10428194.2017.1304762.
    PubMed     Text format     Abstract available


  415. HARIVENKATESH N, Kumar L, Bakhshi S, Sharma A, et al
    Do polymorphisms in MDR1 and CYP3A5 genes influence the risk of cytogenetic relapse in patients with chronic myeloid leukemia on imatinib therapy?
    Leuk Lymphoma. 2017 Apr 3:1-9. doi: 10.1080/10428194.2017.1287359.
    PubMed     Text format     Abstract available


  416. ROBESOVA B, Jeziskova I, Krejci M, Mayer J, et al
    Genesis of new allele at locus D2S1360 in leukemia patient.
    Leuk Lymphoma. 2017 Apr 3:1-4. doi: 10.1080/10428194.2017.1307363.
    PubMed     Text format    


  417. BEAUPIN LK, Bostrom B, Barth MJ, Franklin I, et al
    Pegaspargase hypersensitivity reactions: intravenous infusion versus intramuscular injection - a review.
    Leuk Lymphoma. 2017;58:766-772.
    PubMed     Text format     Abstract available


    March 2017
  418. RAFELSON WM, Reagan JL, Fast LD, Lim SH, et al
    Immunotherapy of elderly acute myeloid leukemia: light at the end of a long tunnel?
    Leuk Lymphoma. 2017 Mar 28:1-9. doi: 10.1080/10428194.2017.1306646.
    PubMed     Text format     Abstract available


  419. CHEN X, Othus M, Wood BL, Walter RB, et al
    Flow cytometric demonstration of decrease in bone marrow leukemic blasts after 'Day 14' without further therapy in acute myeloid leukemia.
    Leuk Lymphoma. 2017 Mar 28:1-3. doi: 10.1080/10428194.2017.1307359.
    PubMed     Text format    


  420. HEISEL RW, Sutton RR, Mascara GP, Winger DG, et al
    Vancomycin-resistant enterococci in acute myeloid leukemia and myelodysplastic syndrome patients undergoing induction chemotherapy with idarubicin and cytarabine.
    Leuk Lymphoma. 2017 Mar 28:1-8. doi: 10.1080/10428194.2017.1306645.
    PubMed     Text format     Abstract available


    January 2016
  421. GRYGOROWICZ MA, Biernacka M, Bujko M, Nowak E, et al
    Human regulatory T cells suppress proliferation of B lymphoma cells.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Leukemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: